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                        INTRODUCTION
                              The most widely accepted route of administration is the oral route.
Up to 50-60% of total dosage forms are administered by oral route. Of this, the most
commonly used dosage form for pharmaceutical preparation is tablet. Tablets, as a dosage
form offer many advantages. They are cost effective, convenient to dispose and store and
easy for the patient to administer. 
                                   When a new drug is discovered, one of the first questions that arise
is whether the drug can be effectively administered for its intended effect by the oral
route.  They  are  the  first  formulations  for  any  new  drug.  If  the  drug  cannot  be
administered by this route, then it is relegated to administration in a hospital setting.
                                     Tablets may be defined as a solid pharmaceutical dosage form
containing  drug  substances  with  or  without  suitable  diluents  and  prepared  either  by
compression or molding methods. Although are frequently discoid in shape, they may
also be round or oblong amongst many other shapes. They may vary in size and weight
depending  on  the  amount  of  drug  substance  present  and  the  intended  method  of
administration. Tablets can be classified as follows depending on the function and route
of administration.
TYPES OF TABLETS:
A. Oral Tablets for Ingestion: 
i. Standard Compressed Tablets
ii. Modified Release Tablets
iii. Delayed Action Tablets
iv. Targeted Tablets
v. Chewable Tablets
vi. Dispersible Tablets
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vii. Multi Compressed Tablets
a. Compression Coated Tablets
b. Layered Tablets
c. Inlay Tablets
B. Tablets Used in Oral Cavity
i. Lozenges and Troches
ii. Sublingual Tablets
iii. Buccal Tablets
iv. Dental Cones
v. Mouth Dissolved Tablets
C. Tablets Administered by Other Routes
i. Vaginal Tablets
ii. Implants
D. Tablets Used to Prepare Solutions
i. Effervescent Tablets
ii. Hypodermic Tablets
iii. Soluble Tablets
Tablets, as dosage forms, suffer their share of disadvantages, despite their wide usage.
Some of them are formulation of drugs that resist compression; bioavailability problems;
unpalatable taste; swallowing problems in pediatric and geriatric patients; difficulty in
administration to patients suffering from severe nausea. 
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                   Pharmaceutical suspensions are uniform dispersions of solid drug particles in
a vehicle in which the drug has minimum solubility.  These are usually formulated to
improve chemical  stability of drug, mask the unpleasant taste and in instances where
liquid dosages form is preferred. Suspension as a dosage form, however, is associated
with issues such as microbial growth, sedimentation and non uniformity of dose, high
cost of manufacturing, difficult to carry, etc. 
                Solid oral dosage forms are most convenient from patient as well as from
manufacturing chemist’s perspective. They ensure uniformity of dosage, are most robust,
have less biological issues compared to liquid dosage forms. However, immediate release
tablets cannot act as a substitute for suspension. Thus, there is a need for a formulation,
which overcomes the problems associated with the swallowing of the solid dosage forms
and act as a viable substitute for suspensions. One such dosage form is dispersible tablets.
Dispersible tablets are defined in Ph. Eur. are uncoated or film coated tablets intended to
be dispersed in water before administration giving a homogenous dispersion. Usually,
about 10-15 ml of water is used and the resulting dispersion is administered to the patient.
However, they can also be placed directly on the tongue and sucked
.
            Figure1:Step by step representation of disintegration process of a dispersible
tablets.
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 Dispersible tablets are required to disintegrate within 3 minutes in water at 15-25 C.
Also the dispersion produced from a dispersible tablet should pass through a sieve screen
with a nominal mesh aperture of 710 microns. The dispersion properties of dispersible
tablets  can  be  facilitated  by  the  inclusion  of  an  acid\base  couple  in  which  the  base
liberates carbon dioxide when the components of the couple are dissolved in water.
IDEAL CHARACTERISTICS OF DISPERSIBLE TABLETS:
• They require water or other liquid at the time of administration.
• Should easily disintegrate and dissolve.
• Mask or overcome unpalatable taste of the drug.
• They should have high drug loading.
• They should have pleasant feel in the mouth.
• They should have low sensitivity against environmental conditions like moisture,
temperature, etc.
• Ease  of  administration  for  patients  who  are  mentally  ill,  disabled  and
uncooperative.
• Should be portable without fragility concern.
• They  should  be  manufactured  using  conventional  tablet  processing  and
packaging equipment at low cost.
SPECIAL FEATURES OF DISPERSIBLE TABLETS:
Dispersible tablets are not intended to be chewed or swallowed whole. They should not
be dispersed in carbonated drinks or milk due to foaming or slow dispersion. The purpose
of dispersible tablet is to provide a unit dosage form of medication which can be easily
administered  to  infants  and  children  or  to  the  elderly,  who  may  have  difficulty
swallowing an intact tablet.
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ADVANTAGES OF DISPERSIBLE TABLETS:
• They are particularly suitable both for elderly and children.
• Rapid disintegration and absorption along with quick onset of action.
• Certain dispersible tablets can also be divided.
• The bitter taste is masked.
• Patient compliance.
• Convenient to carry, easy to manufacture and stable.
• Improved bioavailability, reduced side effects.
LIMITATIONS OF DISPERSIBLE TABLETS:
One common limitation of these formulations is  settling of the insoluble solids at  the
bottom of the container of the prepared dispersion, which may lead to the loss of part of
the drug during administration, resulting in suboptimal dosing. 
DISADVANTAGES OF DISPERSIBLE TABLETS:
•  Lack mechanical strength. Light weight and fragile. Patients should be advised
not to push the tablets through the foil  film, but instead peel the film back to
release the tablet.
• Susceptible to degradation via temperature and moisture. 
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TABLE NO.1, Dispersible tablets available  for common disease:
DISEASE CONDITION DISPERSIBLE TABLETS AVAILABLE
Tuberculosis Rifampicin/ Isoniazid
Diarrhea Zinc sulfate
Malaria
Artemether/ Lumefanatrine (AL),
Artesunate+Amodiaquine
HIV Lamivudine/ Stavudine
Pneumonia
Amoxicillin, amoxicillin/Clavulanate, 
Sulfamethoxazole/ Trimethoprim
Pain and fever Paracetamol
DEVELOPMENTAL CHALLENGES IN DISPERSIBLE DRUG DELIVERY
• Ease of administration:
 These systems are easy to administer and handle hence, leads to better patient
compliance.  Usually,  geriatric  and  pediatric  patients  experience  difficulty  in
swallowing the conventional dosage forms because of tremors of extremities and
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dysphasia.  Fast  Dissolving  Delivery  Systems  may  offer  a  solution  for  these
problems.
• Taste of the active ingredient: 
Some drugs have relatively no taste, and simply adding a suitable flavor can hide
any unpleasant sensation. However, most drugs require taste masking if they are
to be incorporated into dispersible formulations. Simple wet granulation or roller
compression with other excipients to minimize the presented surface area of the
drug is one of the methods used to achieve this purpose. Spray coating can also be
used.  Coating  can  be  done  using  coating  material  such  as  HPMC,  EC,
methacrylate and PVP. Cyclodextrins have been shown to provide some degree of
taste masking by trapping the drug within the cyclic  structure long enough to
render initial dissolution. Electrochemical, hot-melt and supercritical fluid coating
can also be used. 
• Dose: 
High dose drugs present challenges to development of dispersible formulations
which include, 
a. Taste masking of active ingredient
b. Mouth feel or grittiness
c. Tablet size
The degree of bitterness along with the relative dose of the drug will affect the
final tablet size. For example, coating of a tablet to mask the taste may increase
the size of the tablet. The extent to which this increase will affect the mouth feel
and tablet size will depend on the dose of the drug and the amount of coating
material required for masking the taste.
• Hygroscopicity:
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 Several fast dissolving drugs are hygroscopic and cannot maintain integrity under
normal conditions of temperature and humidity. Hence they require protection from
humidity that calls for specialized product package.
• Friability:
 In order to allow dispersible tablets to disintegrate rapidly in the mouth, they are
made of either very porous or soft molded matrices or compressed into tablets with
low compression force, which make the tablet friable and difficult to handle, often
requiring peel off blister packing.
• Mouth feel:
 patients  should receive a  product  that  is  pleasant.  Any large particles  which are
insoluble or slowly soluble in the mouth will lead to an unpleasant or gritty feel. This
can  be  avoided  by  keeping  the  particle  size  limits  below  the  detectable  size.
Effervescence and flavor can be added to improve the feel.
TABLET MANUFACTURING METHODS
There are three basic methods of manufacture:
• Direct compression
• Dry granulation
• Wet granulation
GRANULATION: 
Primarily granules are prepared to improve flow and compression characteristics of the
blend. But there are many other reasons, sometimes, multiple reasons for granulation,
such as:
• Improving flow properties and hence uniformity of dose.
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• Increasing the bulk density of the product.
• Facilitating metering or volumetric dispensing.
• Controlling the rate of drug release.
• Decreasing dust generation and employee exposure to the product.
• Improving product appearance.
Wet granulation
This is the most widely used process of granulation in the pharmaceutical industry.  It
involves the addition of a liquid to powders, to form a wet mass or it forms granules by
adding the powder together with an additive. The wet mass is then dried and sized to
obtain granules. The liquid added binds the moist powder particles by a combination of
capillary and viscous forces in the wet state. More permanent bonds are formed during
the subsequent drying state which leads to the formation of agglomerates.
Steps involved:
• Mixing of drugs and excipients
• Preparation of binder solution
• Mixing of binder solution with powder mixture to form a wet mass
• Coarse screening of wet mass using a suitable sieve
• Drying of moist granules
• Screening of dry granules through a suitable sieve
• Mixing of screened granules with disintegrants, glidant and lubricant
• Compression to form tablets
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Dry granulation:
 In dry granulation process, the powder mixture is compressed without the use of heat and
solvent. It is the least desirable of all methods of granulation. The two basic procedures
are to form a compact material by compression and then to mill the compact to obtain
granules. Two methods are used for dry granulation. The most widely used method is
slugging, where the powder is pre compressed and the resulting tablets or slugs are milled
to yield the granules. The other method is to pre compress the powder with pressure rolls
using a machine such as chilosonator.
Advantages
The main advantages of dry granulation or slugging are that it uses less equipment and
space. It eliminates the need for binder solution, heavy mixing equipment and the costly
and time consuming drying step involved in wet granulation. Slugging can be used for
advantages in the following situations:
• For moisture sensitive material.
• For heat sensitive material.
• For improved disintegration since powder particles are not bound together by a
binder.
Disadvantages 
• It requires a specialized heavy duty tablet press to form slugs.
•  It does not permit uniform color distribution achieved with wet granulation where
the dye can be incorporated into the binder liquid.
• The  process  tends  to  increase  the  production  of  dust  which  may  cause
contamination.
Steps involved:
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• Milling of drugs and excipients
• Mixing of milled powders
• Compression into large, hard tablets to make a slug
• Screening of slugs
• Mixing with lubricants and disintegrating agents
• Tablet compression
Slugging: granulation by slugging is the process of compressing dry powder of tablet
formulation with tablet press having die cavity large enough in diameter to fill quickly.
The accuracy and condition of the slug is not too important. Only sufficient pressure to
compact the powder into uniform slugs should be used. Once slugs are produced they are
reduced to appropriate granule size for final compression by screening and milling. 
Roller compaction: The compaction of powder by means of pressure roll can also be
accomplished by a machine called chilosonator. Unlike tablet machine, the chilosonator
turns out a compact mass in a steady continuous flow. The powder is fed between the
rollers  from  the  hopper  which  contains  a  spiral  auger  to  feed  the  powder  into  the
compaction zone. Like slugs, the aggregates are screened or milled for production into
granules. 
PRINCIPLE
The dispersible tablets are mainly based on the principle of employing super disintegrants
in their formulation which at low concentrations,  facilitate quick disintegration of the
tablets.  An  ideal  disintegrants  should  have  poor  solubility,  poor  gel  formation,  good
hydration  capacity,  good  compressibility,  flow  properties  and  no  tendency  to  form
complexes with the drugs.
                              As superdisintegrants are of prime importance, a careful selection of
superdisintegrants based on the following factors is critical in the formulation.
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• The  disintegrants  must  possess  quick  wicking  action  for  generating  the
hydrostatic pressure required for faster disintegration.
• Smaller particles are preferred over larger particles as the latter produce gritty
mouth  feel.  The  gel  forming  superdisintegrants  are  avoided  for  patient  non-
compliance.
• A more compactable superdisintegrant is preferred to avoid friability.
Method of addition of superdisintegrants:
• INTERNAL ADDITION: 
In wet granulation method, the superdisintegrant is added to the other excipients
before wetting the powder with the granulating fluid to incorporate it within the
granules. Whereas, in dry granulation method, the superdisintegrant is added to
other excipients before compressing the powder between the rollers.
• EXTERNAL ADDITION:
In both wet and dry granulation methods, the superdisintegrant is added to the
granules during the dry mixing step prior to compression.
• INTERNAL AND EXTERNAL ADDITION: 
In  this method, disintegrants is divided into two portions. Ne portion is added
before granule formation and the remaining is added to granules with mixing prior
to compression. The former is  called intra granular disintegrants and the latter
inter granular disintegrants. If both methods are used, the inter granular portion
break the tablet into granules and the intra granular portion will help break the
granules to release the drug substance into solution.
MECHANISM OF ACTION OF SUPERDISINTEGRANTS
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The various mechanisms of disintegration are:
1. Swelling:   High swelling force is observed in tablets with low porosity and
vice  versa.  During  swelling  the  adhesiveness  of  the  other  ingredients  is
considerably reduced and thereby facilitates the disintegration of the tablet.
             
               
Figure2:Swelling action:Particles swell and breakup the particles
2. Wicking: The main principle involved here is porosity and capillary action.
Liquid is drawn up or “wicked” into these pathways through capillary action
and rupture the inter particulate bonds causing the tablet to break apart.
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Figure3:Wicking action:Water is pulled by the disintegrant and reduces
the physical bonding force between the particles..
3. Electrostatic  repulsion: In  this  mechanism  water  is  required  for
disintegration  which  is  mainly  due  to  electrostatic  repulsions  between  the
particles.  Wicking  may  sometimes  be  the  secondary  mechanism  of
disintegration in such cases.
                  
                         Figure4:Deformation and repulsion of particles
Table no.2,List of commonly used super disintegrants.
Superdisintegrant Mechanism of action Properties
Crosscarmellose sodium Swells 4-8 folds in less 
than 10 seconds
Swells in two dimensions
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Swelling and wicking both Direct compression or granulation
Crospovidone
Swells very little and 
returns to original size after
compression but act by 
capillary action
Water insoluble and spongy
in nature so gives porous 
tablets
Sodium starch glycolate Swells 7-12 folds in less than 30 seconds
Swells in three dimensions 
and high level serves as 
sustained release matrix
Calcium silicate Wicking action
Highly porous, light 
weight.
Optimum concentration is 
20-40%
Cross linked alginic acid
Rapid swelling action in 
aqueous medium or 
wicking action
Promotes disintegration in 
both wet and dry 
granulation.
METHOD OF PREPARATION:
1. Spray drying: Spray drying is one of the oldest forms of drying and one of
the few technologies available for the conversion of a liquid to a dry solid.
This  process  is  carried  out  in  three  fundamental  stages.  The  first  stage  is
atomization of  a  liquid feed into  fine droplets.  In  the second  stage,  spray
droplets mix with the heated gas stream and the dried particles are produced
by  the  evaporation  of  the  liquid  from  the  fine  droplets.  The  final  stage
involves the separation of the dried powder from the gas stream and collection
of these powders in a chamber. Allen and Wang produced a particulate support
matrix  for  use  in  dispersible  tablets  by  a  spray  drying  technique.  The
components include supporting agents like non hydrolyzed and hydrolyzed
gelatin, a bulking agent like mannitol and a volatilizing agent.
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2. Lyophilization or freeze drying: Freeze drying or lyophilization is a process
in  which  solvent  is  removed  from a frozen  drug solution or  a  suspension
containing  structure  forming  excipients.  Freeze  drying  process  normally
consists of three steps:
 Material is frozen to bring it below the eutectic point.
 Primary  drying  to  reduce  the  moisture  around  4%  w/w of  dry
product.
 Secondary drying to reduce the bound moisture up to the required
final volume.
The resulting tablets  are  very light  and have highly porous structures  that
allow rapid dissolution or disintegration. The freeze drying process may result
in a glassy amorphous structure of excipients as well as the drug substance
leading to an enhanced dissolution rate.
3. Sublimation: In this technique, highly volatile substances like camphor, urea
and urethane are added to the blend before compression. When highly volatile
substances are compressed, they can be easily removed by sublimation. This
improves the dissolution rate as the end product is a porous structure due to
the evaporation of the volatile substances. Additionally, several solvents like
cyclohexane, benzene etc can also be used as pore forming agents. 
4. Molding:  The molding method is a very effective technique used for taste
masking of  bitter  drugs.  The major components used in this technique are
water soluble. This technique is similar to the conventional tablet compression
technique  except  that  low  pressures  are  used  here.  The  powder  blend  is
moistened with the solvent and the tablet is molded. This process is called
solvent  molding.  The  low compressional  pressure  used results  in  a  porous
structure which leads to enhanced dissolution rates. For further improvement
in the dissolution rate, the powder blend is generally passed through a very
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fine  screen.  The  major  drawback  of  the  molded  tablets  is  that  they  lack
mechanical strength.
                               The molded forms have also been prepared directly from a
molten matrix in which the drug is  dissolved or  dispersed (known as heat
molding) or by evaporating the solvent from a drug solution or suspension at
ambient pressure.
5. Cotton  candy  process: The  process  is  so  named  as  it  utilizes  a  unique
spinning mechanism to produce floss like crystalline structure, which mimic
cotton  candy.  Cotton  candy  process  involves  formation  of  matrix  of
polysaccharides or saccharides by simultaneous action of flash melting and
spinning. The matrix formed is partially recrystallised to have improved flow
properties  and  compressibility.  This  candy floss  matrix  is  then  milled  and
blended with active ingredients and excipients and subsequently compressed
to dispersible tablets. This process can accommodate high doses of drugs and
offers  improved  mechanical  strength.  However,  high  process  temperatures
limit the use of this process.
6. Direct  compression:  This  method  can  be  applied  to  manufacturing
dispersible tablets by choosing appropriate combinations of excipients which
can provide fast disintegration and good physical resistance. This technique us
mainly preferred because of the availability of improved excipients especially
superdisintegrants and sugar based excipients.
a) Superdisintegrants: the addition of superdisintegrants principally affects
the rate of disintegration and hence the dissolution. Tablet disintegration
time can be optimized by concentrating the disintegrants. Below critical
concentration  tablet  disintegration  time  is  inversely  proportional  to
disintegrants  concentration.  Above  the  critical  concentration  level,
however,  disintegration  time  remains  approximately  constant  or  even
increases.
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b) Sugar based excipients: these have been widely used as bulking agents
because of their high aqueous solubility, sweetness, pleasing mouth feel
and  good taste  masking.  Nearly all  formulations  for  dispersible  tablets
incorporate some sugar materials in their formulations. The use of sugar
based excipients especially bulking agents like dextrose, fructose, isomalt,
lactitol,  maltitol,  sorbitol,  starch  hydrolysate,  polydextrose  and  xylitol
which display high aqueous solubility and sweetness and hence impart
taste masking property and pleasing mouth feel. 
7. Nanonization: A recently developed nanomelt technology involves reduction
in  particle  size  of  drug  to  nano  size  by  wet  milling  technique.  Surface
adsorption of the nano crystals of the drug is done on selected stabilizers for
stabilizing them against agglomeration, which are then incorporated in to the
dispersible tablets. This technique is mainly advantageous for poorly water
soluble drugs and also for wide range of doses (up to 200 mg of drug per
unit).
TABLE 3: Advantages and Disadvantages of the different technologies for preparing
rapidly disintegrating pharmaceutical forms.
Technology Advantages Disadvantages
Freeze drying Immediate dissolution. Very poor physical resistance.
High cost of production.
Low dose of water soluble drugs.
Molding Very rapid dissolution.
High dose.
High cost of production.
Weak mechanical strength.
Possible limitations in stability.
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Tableting Low cost of production
Use of standard 
equipment/materials.
High dose.
Good physical resistance.
Disintegration capacity markedly 
limited by the size and hardness of 
the tablets.
TABLE 4: Some examples of marketed products
Marketed Product Active Ingredient Therapeutic Ingredient Manufacturer
Methadose Methadone Narcotic analgesic Gen pharma
Voltarol Diclofenac sodium NSAID Alpa pharma
Clarinex Redi Tabs Desloratidine Anti-histamine Yash pharma
Riamet Artemether and Lumefanatrine Anti malarial Novartis Australia
Lamotrigine Lamotrigine Anti epilepsy and bipolar disease Actavis
Ranmoxy distab Amoxicillin trihydrate Anti bacterial Ranbaxy
Rapidol Paracetamol Analgesic and 
antipyretic
Ethypharm 
industries, France
Analtra-DT Tramadol HCl Central analgesic May Flower, India
Azcin-DT Azithromycin Macrolide antibiotic West coast pharmaceuticals
C Pod dispersible 
tablets
Cefpodoxime 
Proxetil Antibiotic
Yash pharma 
laboratories
Dispersible 
acyclovir tablets Acyclovir Antiviral
Yash pharma 
laboratories
Lovan tablets Fluoxetin HCl SSRI Alphapharm P/L
Ivamer Ivermectin Anti helminthetic Gen pharma
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Ivaver DT plus Ivermectin and Albendazole Anti helminthetic Gen pharma
Cefocef LB Cefixime trihydrate Cephalosporin 
antibiotic Centaur pharma
Piram D Piroxicam NSAID Mylan laboratories
Montasma Montelukast 
sodium
Leukotriene receptor
antagonist Icarus healthcare
TABLE 5: Marketed technologies of fast disintegrating tablets
Patented 
technology
Technique 
employed
Innovator 
company
Active ingredient and
brand names Advantages
Zydis Lyophilization R. P Scherer Corp
Loratidine (Claritin, 
Reditab 
pharmaceuticals)
Highly porous
Durasolv Molding CIMA Labs
HyoscymineSulphate
(NuLev)
Good rigidity
Wowtab Compression 
molded tablets
Yamanouchi 
Pharma Famotidine (Gaster D)
Adequate 
dissolution rate
Flashdose Cotton Candy Process
Fuisz Technology 
Ltd
Tramadol 
Hcl(Reliviaflash dose)
Highly porous in
nature,it shows 
pleasant 
mouthfeel 
property
Flashtab Effervescent Disintigrant Prographarm Group
Ibuprofen(Nurofen 
Flash dose)
Conventional 
tabletting 
technology
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Ziplets Molding EurandInternational Ibuprofen(Cibalgina due fast)
Sufficient 
mechanical 
strength
Oraquick Micromask taste KV Pharma co,inc
Hyoscyamine sulfate 
ODT
Significant 
friability is 
present in tablets
CHELATORS: 
Chelators are small molecules that bind very tightly to metal ions. Some Chelators are the
molecules that can be manufactured [e.g. ethylene diamine tetra acetic; EDTA]. The other
Chelators are proteins made by living organisms [e.  g.  transferrin].  The key property
shared by all Chelators is that the metal ion bound to the Chelators is chemically inert.
Consequently,  one  of  the  important  roles  of  Chelators  is  to  detoxify metal  ions  and
prevent poisoning.
Chelating agents were introduced into medicine as a result of the use of poison gas in
World  War-1.  The  first  widely  used  chelating  agent,  the  organic  dithiol  compound
dimercaprol [also named British Anti- Lewisite or BAL], was used as an antidote to the
arsenic-based  poison  gas,  Lewisite.  The  sulphur  atoms  in  BAL’s  mercaptan  groups
strongly bond to the arsenic in Lewisite, forming a water-soluble compound that entered
the bloodstream, a allowing it to be removed from the body by the kidneys and liver.
BAL had severe side-effects.
After World War -11, a large number of navy personnel suffered from lead poisoning as a
result of their jobs repainting the hulls of ships. The medical  use of EDTA as a lead
chelating agent was introduced. Unlike BAL, it is a synthetic amino acid and contains no
mercaptans. EDTA side effects were not considered as severe as BAL.
In the 1960s, BAL was modified into DMSA, a related dithiol with far fewer side effects.
DMSA quickly replaced both BAL and EDTA, becoming the US standard of care for the
treatment of lead, arsenic, and mercury poisoning, which it remains today.
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Research in the former Soviet Union led to the introduction of DMPS, another dithiol, as
a mercury-chelating agent. The Soviets also introduced ALA, which is transformed by the
body into dithiol dihydrolipoic acid, a mercury and arsenic-chelating agent. DMPS has
experimental status in the US FDA, while ALA is a common nutritional supplement. 
Since  the  1970s,  iron  chelating  therapy  has  been  used  as  an  alternative  to  regular
phlebotomy to treat excess iron deposition in people with haemochromatosis.
Several  chelating agents are  available,  having different  affinities  for  different  metals.
Common chelating agents include:
• Alpha lipoic acid (ALA) 
• Aminophenoxyethane-tetra acetic acid (BAPTA) 
• Deferasirox
• Deferiprone
• Deferoxamine
• Diethylene triamine penta acetic acid (DTPA) 
• Dimercaprol (BAL)
• Dimercapto propane sulfonate (DMPS)
• Dimercaptosuccinic acid (DMSA)
• Ethylenediamine tetra acetic acid(calcium disodium versanate) (CaNa2-EDTA)
• Ethylene glycol tetra acetic acid (EGTA)
• D-penicillamine
IRON OVERLOAD
Arulmigu kalasalingam college of pharmacy Page 22
Department  of pharmaceutics
                                                                                                                                            INTRODUCTION
Iron overload is the result of many disorders and can lead to the development of organ
damage  with  increased  mortalities.  In  humans,  total  body  iron  concentrations  are
maintained  within  the  range  of  200-1500 mg by inadequate  adjustment  of  intestinal
absorption,  since  no  excretory  mechanisms  exist.  In  normal  individuals,  feedback
mechanisms inhibit iron absorption as storage iron increases. Each condition that induces
an increased net entry of iron within the body inevitably leads to iron overload. It can be
classified as primary or secondary depending whether it results from a primary defect in
the regulation of iron balance or acquired disorders. A known example of primary iron
overload is hereditary haemochromatosis [HHC], in  which iron is absorbed in excess
because of increased iron transfer  from the enteral  cells  to the blood. The secondary
includes  iron  overload  either  due  to,  or  associated  with,  ineffective  erythropoiesis,
chronic  liver diseases,  parenteral  administration or  ingestion of  excessive amounts  of
iron.  Thalassemia  major  and  sideroblastic  anemia  are  the  two best  examples  of  iron
overload secondary to blood transfusions and ineffective erythropoiesis. Frequent blood 
transfusions lead to excessive accumulation of iron with a toxic accumulation in 3-10
years. 
                           The toxicity of iron results from two related events:
1. Excess iron concentration in various tissues of the body,  particularly in  liver,
heart  and  endocrine  organs  with  the  consequence  of  liver  diseases,  diabetes
mellitus and other complications.
2. Free iron that catalyses the formation of highly reactive hydroxyl radicles which
lead to membrane damage and denaturation of proteins.
Once  iron  exceeds  a  certain  level,  these  effects  lead  to  significant  morbidity  and
mortality.  Without specific chelation therapy to remove iron,  in 3-10 years  almost  all
regularly transfused patients will have acquired a toxicity of iron.  The main cause of
death is cardiac complications. 
Treatment of iron overload:
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The aim of treatment of iron storage disease is to remove from the body the excess iron
that has accumulated. This can be done by employing iron Chelators. Iron Chelators can
be classified using a number of criteria such as their origin (synthetic versus biologically
produced molecules), their interaction with solvents such as water (hydrophobic versus
hydrophilic) or their stoichiometric interaction (bidentate versus hexadentate). Some of
these properties have an important impact on the clinical utility of the chelator. One of the
key clinical features is the degree to which they are absorbed from the gastrointestinal
tract.  
                                     Figure5:Mechanism of action of iron chelater
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By increasing the dose of Chelators in an attempt to speed up iron removal, there is a risk
of increasing toxicity of iron Chelators by chelating iron, which is needed for normal
tissue metabolism. Therefore, while the slow process of decreasing tissue iron to safe
levels is being achieved; second goal is to make the iron as safe as possible by binding
the toxic iron pools responsible for causing tissue damage. Iron chelation therapy reduces
iron related morbidity, reduces and retards liver diseases, diabetes and other endocrine
failures, normalizes growth and sexual development, prevents, and in some cases reverses
cardiac insufficiency and improves quality of life. 
TABLE 6: Available iron chelating agents used for the treatment of iron overload.
Agent Brand 
name(manufacturer) Pharmacology
Route of 
administratio
n
Deferasirox Exjade (Novartis) Tridentate molecule; 2:1
stoichiometry for iron Oral
Deferiprone Ferriprox (Apotex) Bidentate molecule; 3:1 
stoichiometry for iron Oral
Deferoxamine Desferal (Novartis)
Hexadentate molecule; 
1:1 stoichiometry for 
iron
IV
 Excipients  used in the formulation of dispersible tablets:
Excipients  are  inert  substances  used  as  diluents  or  vehicles  for  a  drug.  In  the
pharmaceutical  industry  it  is  a  catch  all  term  which  includes  various  sub  groups
comprising diluents or fillers, binders or adhesives, disintegrants, glidants, flavors, colors
and sweetners. All of these must meet certain criteria as follows:
 They must be physiologically inert.
 They must be acceptable to regulatory agencies.
 They must be physiologically and chemically stable.
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 They must  be  free  of  any bacteria  considered  to  be  pathogenic  or  otherwise
objectionable.
 They must not interfere with the bioavailability of the drug.
 They must be commercially available in the form and purity commensurate to
pharmaceutical standards.
 Cost must be relatively inexpensive.
 They must confirm to all regulatory requirements.
To assure that no excipient interferes with the utilization of the drug, the formulator must
carefully and critically valuate combinations of the drug with each of the contemplated
excipients and must as certain compliance of each ingredient with existing standards and
regulations.
The screening of drug-excipient and excipient-excipient interactions should be carried out
routinely  in  pre  formulation  studies.  Determination  of  the  optimum  drug-excipient
compatibility has been adequately presented in the literature.
TABLE 7: List of excipients used in the formulation of dispersible tablets
Excipients Function Example
Diluents
Fillers used to make the required bulk of
the tablet.
Also used as disintegrants in the 
dispersible and orally disintegrating 
tablets.
Secondary function is to provide better 
tablet properties like improve cohesion, 
flow, compactibility, stability, etc.
Lactose, spray dried lactose, 
microcrystalline cellulose 
(Avicel 101 and 102), mannitol
(Pearlitol SD200 and 25 C), 
sorbitol, dibasic calcium 
phosphate dehydrate
Binders Impart cohesive strength to powdered 
materials
Gelatin, glucose, lactose, 
cellulose derivatives, EC, 
HPMC, PVP, CMC, acacia etc
Superdisinte
grants
They facilitate tablet breaking when it 
comes in contact with water in oral 
cavity/ GIT
Ac-di-sol, Crospovidone, 
starch, sodium starch glycolate.
Lubricants Prevent adhesion of tablet material to 
dies and punches, reduce interparticulate
friction.
Insoluble-stearic acid, 
magnesium state, talc, calcium 
stearate.
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Facilitate easy ejection of tablet from 
dies.
Soluble- SLS, PEG-
400,600,800 etc
Glidants Reduce friction between the particles 
and improve flow properties
Colloidal silicon dioxide, corn 
starch, talc.
Ant 
adherents
These are added to prevent adhesion of 
tablet material to punches and dies. Talc
Sweetners To produce a palatable dosage form Sucrose, sucralose, saccharin, 
aspartame etc
Flavors Improve taste of dosage form Peppermint, vanilla, orange, banana, cinnamon,
Colors For better appearance Sunset yellow
Packaging of dispersible tablets:
Some of the dispersible tablets are stable during storage, E.G., for two years or even 3
years in conventional packing and these type of dosage forms are stored in HDPE bottles,
strip packs and blister packs.  
Arulmigu kalasalingam college of pharmacy Page 27
Department  of pharmaceutics
                                                                                                                                         AIM &OBJECTIVE
          AIM AND OBJECTIVE
The  objective  of  the  current  study  was  to  development  optimize   a  oral
disintegration tablets. Deferasirox  is a rationally designed oral Iron chelator.
  Its main use is to reduce chronic Iron overload in patients who are receiving long
term blood transfusions for conditions . such as “beta-thalassemia”.
 It  is  the first  oral  medication of  oral  disintegration  tablets were prepared by
direct compression method using different super disintegrating agents .   such as cross
povidone, sodium starch glycolate & cross carmellose sodium.
The main objective of this study was .
 To  perform  reformulation  studies.  To  formulate  deferasirox  oral  dispersible
tablets.  To  select  formulation  based  on  invitor  studies  of  oral  dispersible  tablets.  To
perform stability studies  on  the  most  satisfactory formulation.  To correlate  innovator
product.To  formulate  deferasirox  oral  dispersible  tablets.  To  obtain  a  suitable  dosage
form of  better “taste masking & invitro drug release”.   
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PAST WORK CARRIED ON DEFERASIROX:
Elliott Vichinsky  et. al., (2007)  evaluated the safety and tolerability of Deferasirox in
comparision with Deferoxamine in this population. Assessment of efficacy, as measure by
the change in liver iron concentration (LIC) using biosusceptometry,  was a secondary
objective.  A total  of 195 adult  and pediatric patients received Deferasirox (n=132) or
Deferoxamine (n=63). Adverse events most commonly associated with Deferasirox were
mild,  including  transient  nausea,  vomiting.  Diarrhea,  abdominal  pain  and  skin  rash.
Abnormal laboratory studies with Deferasirox were occasionally associated with  mild
non progressive increase in serum creatinine and reversible elevations in liver function
tests.  Discontinuation rates  from Deferasirox  and Deferoxamine were similar.  Over  1
year,  similar  dose-dependant  LIC  reductions  were  observed  with  Deferasirox  and
Deferoxamine.  Once daily oral  Deferasirox  has  acceptable tolerability and appears  to
have similar efficacy to Deferoxamine in reducing iron burden in transfused patients with
sickle cell disease.
Brad et. al., (2009) described the safety profile of open-label, adjunctive Deferasirox iron
chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was
administered  for  an  average  of  14  days  [range,  7  to  21]  at  5  to  20  mg/kg  of  body
weight/day.  The  only  adverse  effects  attributable  to  Deferasirox  were  rashes  in  two
patients. Deferasirox treatment was not associated with changes in renal or liver function,
complete  blood  count,  or  transplant  immunosuppressive  levels.  Thus,  Deferasirox
appears safe as an adjunctive therapy for mucormycosis.
Renzo Gallenello et. al., (2008) investigated the effect of food and time of food intake on
the pharmacokinetics of Deferasirox on healthy volunteers and patients with transfusional
hemosiderosis. The bioequivalence of a single oral dose of Deferasirox (20 mg/kg) was
assessed  following  administration  either  before  a  high  fat  or  standard  breakfast  or
concurrent with a standard breakfast  in comparision with fasted conditions in healthy
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volunteers.  The bioavailability of  Deferasirox was determined following a single oral
dose (20 mg/kg) under fed and fasted conditions in patients. These data showed that the
type of  food,  calorie  content  and  fat  content  of  the meal influence  bioavailability of
Deferasirox  when  consumed  concurrently.  In  conclusion,  it  is  recommended  that
Deferasirox be administered atleast 30 mins before meals.
Romain Sechaud et. al., (2008) evaluated the absolute bioavailability of a single 375 mg
oral dose of Deferasirox administered in the form of a tablet compared with a 130 mg
intravenous infusion of Deferasirox. The main study phase consisted of 17 healthy male
volunteers.  Plasma  concentrations  of  Deferasirox  were  measured  following  each
treatment, and pharmacokinetic parameters including absolute oral bioavailability were
determined.  Absolute  oral  bioavailability  of  the  Deferasirox  tablets  was  70%  (90%
confidence interval, 62%-80%).
Cappelilini  et.  al.,  (2006)  conducted a comparitive phase III  trial  to demonstrate  the
efficacy of  Deferasirox in  regularly transfused patients with  beta-Thalassemia aged 2
years  or  older.  Patients  were  randomized  and  received  treatment  with  Deferasirox
(n=296) or Deferoxamine (n=290), with dosing of each according to baseline liver iron
concentration  (LIC).  The  primary  end  point  was  maintenance  or  reduction  of  LIC;
secondary end points included safety and tolerability, change in serum ferritin level, and
net body iron balance.
Deborah Chirnomas  et. al.,  (2009)  performed a prospective study of oral Deferasirox
pharmacokinetics (PK),  comparing 10 transfused patients with inadequate Deferasirox
response (rising ferritin trend or rising liver iron on Deferasirox doses >30mg/kg per day)
with control transfusion dependant patients (n=5) with adequate response. Subjects were
admitted  for  4  assessments:  Deferoxamine  infusion,  urinary  iron  measurement,
quantitative hepatobilary scintigraphy, a 24 hour Deferasirox PK study following a single
35  mg/kg  dose  of  oral  Deferasirox;  and  pharmacogenomic  analysis.  Patients  with
inadequate  response  to  Deferasirox  had  significantly  lower  systemic  drug  exposure
compared with control patients (p< 0.00001). Cmax, V volume  of  distribution/
bioavailability and elimination half life were not different between the groups, suggesting
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bioavailability  as  the  likely  discriminant.  Effective  dosing  regimens  for  inadequately
responding patients to Deferasirox must be determined.
Andrej  Skerjanee  et.  al.,  (2010)  investigated  the  pharmacokinetic  interactions  of
Deferasirox with Midazolam, Rifampicin and Repaglinide in healthy volunteers. In the
induction  assessment,  single  dose  Deferasirox  pharmacokinetics  was  obtained  in  the
presence and absence of a repeated dose regimen of rifampin. In the CYP3A interaction
evaluation,  midazolam in  the  presence  and  absence  of  steady state  concentrations  of
Deferasirox.  To  test  for  interaction at  the level  of  CYP2C8,  single  dose Repaglinide
pharmacokinetics/pharmacodynamics were determined with and without repeated dose
administration of Deferasirox. After rifampin, a significant reduction (44%) in AUC to
Deferasirox was observed. Upon co administration of midazolam, there was a modest
reduction  of  up  to  22%  in  midazolam  exposure  (AUC,  Cmax),  suggesting  a  modest
induction  of  CYP3A4/5  by  Deferasirox.  Deferasirox  caused  increase  in  Repaglinide
plasma Cmax and AUC of 1.5 fold to over 2 fold, respectively, with little change in blood
glucose measures.
Schienfled  et.  al., (2007)  reviewed the  dermatologic uses and effects  of Deferasirox,
bortezomib, dastinib and cyclosporine eye drops. He reviewed that Deferasirox, an oral
iron  chelator  could  be  an  effective  treatment  against  porphyria  cutanea  tarda,
haemochromatosis and pathogens such as mucor that thrive in iron rich environments.
REVIEW OF WORK DONE ON DISPERSIBLE TABLET:
Sandeep patil  B et al   Formulated quick dispersible  tablet  of  olanzapine by
direct compression method. Effect of super disintegrant crospovidone on wetting time,
disintegration time, drug content & in-vitro release has been studied. Disintegration time
decreased  and  percent  drug  dissolved  increased  with  increase  in  the  level  of
crospovidone.
Kuchekar BS et al   Formulation dispersible tablets of norfloxacin using natural
substances as disintegrants such as isapghula husk powder, Cassia tora powder(defatted)
and Cassia nodosa powder in different concentration by direct compression method. The
study reveals that natural gums used as disintegrants were effective in low concentration.
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Snehalatha et al   Formulated dispersible tablets of piroxicam using different
natural disintegrants in order to get required theoretical release profile. The influence of
the disintegrant concentration and granulation technique on the release of piroxicam was
studied. The study reveals that the formulation prepared by direct compression exhibits
better  dissolution,  disintegration  at  low  concentration  of  distegration  of  natural
distintegrants.
Mohanachandran et al   Formulated mouth dispersible  tablets of  amlodipine
besylate by direct compression method using different super disintegrants. FDT’s were
evaluated for its physicochemical properties and  in-vitro dissolution. Effect of different
superdisintegrant on disintegration behavior of tablets was evaluated in phosphate buffer
pH  7.2.  All  formulations  were  evaluated  for  pre-compression  and  post-compression
parameters. Wetting time of formulations containing crosscarmellose sodium was least
and  tablets  showed  faster  disintegration.  FT-IR  studies  revealed  that  there  physio-
chemical interaction between amlodipine besylate and other excipients.
Suresh Kulkarni V et al   Formulated disintegrating meloxicam tablets by wet
granulation  method.  The  influence  of  superdisintegrants,  crosspovidone  and
crosscarmellose sodium on disintegration time, wetting time and water absorption ratio
are studied. Tablets contained crospovidone exhibit quick disintegration time than tablets
containing croscaremellose sodium. The fast  disintegrating tablets of  meloxicam with
shorter disintegration time, acceptable taste and sufficient hardness could be prepared
using crospovidone and other excipients at optimum concentration.
Avani  Gosai  R  et  al formulated  oro-dispersible  tablets  of  ondansetron
hydrochloride  by direct  compression  using  super-disintegrants  such  as  sodium starch
glycolate  and  croscarmellose  as  superdisintegrants,  as  the  combination  of  these  two
agents gives better disintegration of the tablet. Dissolution study revealed faster release
rate  of  ondansetron  hydrochloride  from  the  tablets  as  compared  to  pure  drug  and
marketed conventional tablet formulation of andansetron hydrochloride. It was concluded
that superdisintegrants addition technique is a useful method for preparing oro dispersible
tablets by direct compression method.
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 Pre formulation studies of excipients and their compatibility with the API.
 Innovator product evaluation.
 Development of various formulations and preparation of dispersible tablets by
 Direct compression method
 Wet granulation technique
 Selection and optimization of the best formulation.
 Comparision of the optimized formulation with the innovator product.
 To  perform stability  studies  on  the  most  satisfactory  formulation  as  per  ICH
guidelines.
I. Pre-compression parameters: 
• Angle of repose 
• Bulk density 
• Tapped density
• Hausner's ratio 
• Compatibility study 
II. Post-compression parameters: 
• Hardness uniformity 
• Uniformity of thickness  
• Friability test 
• Weight uniformity test 
• Drug content uniformity 
• Wetting time  
• In vitro dispersion time 
• In vitro disintegration time
• In vitro dissolution studies
• Final comparisons between evaluated results of direct compression.
Arulmigu kalasalingam college of pharmacy Page 31
Department  of pharmaceutics
                                                                                                                   Materials
LIST OF EQUIPMENTS:
Table 8: List of equipments
Equipments Manufacturer
Electronic balance Mettler-Toledo, USA
Bulk density apparatus Electrolab, Mumbai
Rapid Mixer Granulator (RMG) Anchor Mark Pvt. Ltd.
Rotary Tablet punching machine Rimek, Mumbai
Friability test apparatus Electrolab, Mumbai
Tablet dissolution apparatus Electrolab, Mumbai
Disintegration apparatus Electrolab, Mumbai
Helium lamp (LOD) Mettler-Toledo
Thickness (Vernier Calipers) Mitutogo Vernier Calipers
Environmental Chambers Thermolab
Hot air oven Eltek motors, Mumbai
High performance liquid chromatography
(HPLC)
Waters, Hyderabad
Sieves Jayanth test sieves, Mumbai
Hardness tester Dr.Schleuniger pharmatron USA
Fluidized bed drier Anchor Mark Pvt. Ltd.
 LIST OF CHEMICALS: Table no:9
Ingredients Manufacturer Supplier
Deferasirox Natco Pharma Ltd.,Hyderabad Natco Pharma Ltd, Hyderabad
Crospovidone
XL ISP Technologies Inc, USA Ansul Agencies, Mumbai
Starch 1500 DMV International GmbH, KMV  Enterprises, Hyderabad
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Netherlands
MCC pH 101 FMC Biopolymer, USA Signet Chemical Corporation,Mumbai
MCC pH102 FMC Biopolymer, USA Signet Chemical Corporation,Mumbai
SLS Merck limited, Mumbai Vasco Scientifics Pvt. Ltd.,Secunderabad
Povidone K30 ISP Technologies Inc, USA Signet Chemical Corporation,Mumbai
Aerosil Mayur Chemicals, Mumbai Mayur Chemicals, Mumbai
Magnesium
stearate Ferro Industries Quimica, Portugal
Signet Chemical Corporation,
Mumbai
SSG JRS Pharma, Germany KMV Enterprises, Hyderabad
Tween 80 Merck limited, Mumbai Vasco Scientifics Pvt. Ltd.,Secunderabad
SSF JRS Pharma, Germany Merck chemicals, Mumbai
Talc Luzenac Valchisone, Italy Signet Chemical Corporation,Mumbai
L-HPC-LH11 DMV International GmbH,Netherlands KMV Enterprises, Hyderabad
Lactose
Monohydrate
DMV International GmbH,
Netherlands KMV Enterprises, Hyderabad
Sucralose M.B.Sugars & PharmaceuticalsLimited, Maharastra
Signet Chemical Corporation,
Mumbai
Orange Flavor Firmenich Asia India Pvt. Ltd. Manish Global Industries
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DEFERASIROX:
Category: Iron chelator
Molecular formula: C21H15N3O4
Molecular weight: 373.4
Structural formula:
                              
Chemical name: 4-[3, 4-Bis (2-hydroxyphenyl)-1H-1, 2, 4-triazol-1yl]-benzoic acid
Description:  Deferasirox is a white to slightly yellow powder that is freely soluble in
dimethyl  formamide  and  dimethyl  sulfoxide,  slightly soluble  in  methanol,  practically
insoluble in water.
Indication: Deferasirox is indicated in for the treatment of Chronic Iron Overload due to
blood transfusions in adult and pediatric patients (aged 2 years and over).
Mechanism of action: 
Deferasirox  mobilize  tissue  iron  by  forming  soluble,  stable  complexes  that  are  then
excreted in the feces. It is a tridentate iron chelator requiring two molecules of the drug to
form the stable complex. Iron is chelated,  both from the reticuloendothelial  cells  (RE
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cells) as well as various parenchymal tissues. The chelated iron is cleared by the liver and
excreted  through bile.  It  also  has  the  ability  to  prevent  myocardial  cell  iron  uptake,
remove iron directly from myocardial cells. In fact, ICL 670 readily yields iron to DFO.
In animal models, on molar basis, it has been shown to be 5 times more potent than DFO
and  ten  times  more  potent  than  Deferiprone.  Iron  removal  also  depends  on  plasma
concentration, host factors, degree of loading and rate of accessibility of accumulation
iron to chelator.
Pharmacodynamics: 
Pharmacodynamic  effects  tested  in  an  iron  balance  metabolic  study  showed  that
Deferasirox (10, 20 and 40 mg/kg per day) was able to induce a mean net iron excretion
(0.119, 0.329 and 0.445 mg Fe/kg body weight per day, respectively) within the clinically
relevant range (0.1-0.5 mg/kg per day). Iron excretion was predominantly fecal.
Pharmacokinetics: 
ABSORPTION: 
Deferasirox is absorbed following oral administration with median times to maximum
plasma concentration  (Tmax)  of  about  1.5-4 hours.  The  Cmax and  AUC of Deferasirox
increase  linearly  with  dose  after  both  single  administration  and  under  steady  state
conditions. Exposure to Deferasirox increased by an accumulation factor of 1.3-2.3 after
multiple doses. The absolute bioavailability of Deferasirox tablets for oral suspension is
70% compared to an intravenous dose. The bioavailability was variably increased when
taken with a meal.
DISTRIBUTION:
It is highly protein bound (~99%) almost exclusively to serum albumin. The percentage
of Deferasirox confined to the blood cells was 5% in humans. The volume of distribution
at steady state (Vss) of Deferasirox is 14.37 ±2.69 L in adults.
METABOLISM:
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Glucouronidation is the main pathway with subsequent bilary excretion. Deconjugation
of glucouronides in the intestine and subsequent reabsorption is likely to occur. The drug
is mainly glucouronidated by UGT1A1 and to a lesser extent by UGT1A3. CYP450-
catalysed  metabolism  of  Deferasirox  appears  to  be  minor  in  humans  (about  8%).
Deconjugation of  glucouronides  in  the intestine was confirmed in  a  clinical  study in
which  the  administration  of  cholestyramine  12g  daily  twice  (strongly  binds  to
Deferasirox and its conjugates) 4 and 10 hours after administration after a single dose of
Deferasirox  resulted  in  a  45%  decrease  exposure  (AUC)  by  interfering  with  the
enterohepatic cycling of the drug.mai
EXCRETION:
Deferasirox  and  its  metabolites  are  primarily  excreted  in  the  feces  (~84%).  Renal
excretion of Deferasirox and metabolites is minimal (8% of the administered dose). The
mean elimination half life ranged from 8-16 hours following oral administration. 
Dosage and administration:
Recommended initial daily dose is 20mg/kg body weight.
Maintenance daily dose to be adjusted if necessary every 3 to 6 months based on serum
ferritin trends.
Maximum daily dose is 30mg/kg body weight.
Deferasirox must be taken once daily on an empty stomach at least 30 mins before food.
Deferasirox tablets are dispersed by stirring in a glass of water or apple or orange juice
[100-200ml] until affine suspension is obtained.
Contraindication:
Deferasirox is contraindicated in patients with:
Creatinine clearance <40ml/min or serum creatinine > 2 times the age appropriate upper
limit of normal.
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 Poor  performance  status  and  high-risk  myelodysplastic  syndromes  or  advanced
malignancies.
Platelet counts < 50x 1000000000/l
Hypersensitivity to Deferasirox or to any of the excipients. 
 Drug interactions:
The  concomitant  administration  of  Deferasirox  and  aluminum  containing  antacid
preparations has not been formally studied. Although Deferasirox has a lower affinity for
aluminum than iron, do not administer Deferasirox with aluminum containing antacid
preparations.
Deferasirox is contraindicated in people already taking iron chelator due to an increased
risk of toxicity.
Side effects:
Deferasirox has a manageable side effect profile and when patients do experience side
effects, they are generally mild to moderate and transient.
Gastrointestinal  disturbances  (mainly  nausea,  vomiting,  diarrhea  or  abdominal  pain)
occurred in approximately 26% of patients in clinical trials. Diarrhea was reported more
often in pediatric patients aged 2-5 years than in older children and adults.
Rare cases of anaphylaxis and angiodema have been reported.
Skin rash was seen in 7% of the patients and was mostly mild to moderate and generally
transient.
As with other iron chelator therapy, high frequency hearing loss and early cataracts have
been uncommonly observed.
Warnings: 
Must not be chewed or swallowed whole.
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It should also not be dispersed in carbonated drinks or milk due to foaming and slow
dispersion.
It  should  not  be  combined  with  other  iron  chelator  therapies  as  the  safety  of  such
combinations has not been established.
Renal, hepatic failures and gastrointestinal hemorrhage.
Risks and precautions:
Some reports have been reported of kidney impairment associated with Deferasirox use.
Could cause cytopenia.
Liver failure, sometimes leads to death,  has been reported during treatment of people
with pre existing severe liver damage such as cirrhosis.
Thus tests which determine these functions during this treatment must be carried out.
Dizziness while using Deferasirox, so care should be taken while engaging in activities
requiring alertness such as driving or using machinery.
Storage: 
Store at room temperature at 77 F (25 C), away from light and moisture. Brief storage
between 59-86 F (15-30 C) is permitted. Keep away from children and pets.
Uses: 
The medication is used to treat ongoing high levels of iron in the body caused by multiple
blood  transfusions.  Frequent  blood  transfusions  are  needed  in  certain  types  of  blood
diseases. Blood transfusions have very helpful benefits, but they can cause the body to
hold  onto  too  much  iron.  The  extra  iron  can  build  up  in  various  organs  and  cause
problems such as heart failure, liver disease and diabetes. Getting rid of extra iron can
decrease the risk of these diseases.
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                                      EXCIPIENT PROFILE
LACTOSE, MONOHYDRATE:
Nonproprietary name: Lactose
Synonym: Capsulac, Lactochem, Tablettose.
Chemical name: O-β-D-Galactopyranosyl-(1,4)-α-D-glucopyranose monohydrate.
Empirical name: C12H22O11.H2O
Molecular weight: 360.31
Functional category: dry powder inhaler carrier, lyophilization aid, tablet binder, tablet
and capsule diluents and tablet and capsule filler.
Description: In the solid state, lactose appears as various isomeric forms, depending on
the crystallization and drying conditions. Lactose occurs as white to off white crystalline
powder  or  particles.  Lactose  id  odorless  and  slightly  sweet  tasting;  α-lactose  is
approximately 20% as sweet as sucrose, while β-lactose is 40% as sweet.
Solubility: practically insoluble in chloroform, ethanol and water (1 in 5.24, 1 in 3.05 at
40 C, 1 in 2.30 at 50 C, 1 in 1.71 at 60 C. 1 in 0.96 at 80 C)
Stability  and storage conditions:  mould growth may occur  under  humid conditions.
Lactose may develop a brown color on storage, the reaction being accelerated by warm,
damp conditions. It should be stored in a well closed container in a cool, dry place.
Incompatibilities: a  maillard  type  condensation  reaction  is  likely  to  occur  between
lactose and compounds with a primary amine group to form brown or yellow brown
coloured products. It is also incompatible with amino acids, amphetamines and lisinopril.
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Applications: lactose is widely used as filler and diluents in tablets and capsules, and to a
more limited extent in lyophilized products and infant formulas. Lactose is also used as a
diluents in dry powder inhalations.
Related  substances:  lactose,  anhydrous;  lactose,  inhalation;  monohydrate  and  corn
starch.
                                                    CROSPOVIDONE: 
Nonproprietary name: Crospovidone.
Synonyms: crospovidonum; polyplasdone XL; polyvinyl polypyrrolidone.
Chemical name: 1-Ethenyl-2-pyrrolidone homopolymer
Empirical formula: (C6H9NO) n
Molecular weight: >1, 000, 000
Functional category: tablet disintegrants
Description: Crospovidone  is  a  white  to  creamy-white,  finely divided,  free  flowing,
practically tasteless, odorless or nearly odorless, hygroscopic powder.
Solubility: practically insoluble in water and most common organic solvents.
Stability and storage conditions: since Crospovidone is hygroscopic, it should be stored
in airtight container in a cool and dry place.
Incompatibilities: Crospovidone  is  compatible  with  most  organic  and  inorganic
pharmaceutical ingredients. When exposed to a high water level, Crospovidone may form
molecular adducts with some materials.
Applications: Crospovidone  is  a  water  insoluble  tablet  disintegrants  and  dissolution
agent used at 2-5% concentration in tablets prepared by direct compression or wet and
dry granulation methods. It can also be used as a solubility enhancer.
Related substances: Crospovidone, Povidone.
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                                                               STARCH:  
Nonproprietary name: pregelatinised starch.
Synonyms: compressible starch, Lycatab C, starch 1500 G, Tablitz.
Chemical name: pregelatinised starch.
Empirical formula: (C6H10O5)n where n=300-1000
Functional category: tablet and capsule diluents, tablet and capsule disintegrants, tablet
binder.
Description: pregelatinised starch occurs as a moderately coarse to fine,  white to off
white color powder. It  is odorless and has a slight characteristic taste. Examination of
fully  pregelatinised  starch  as  a  slurry in  cold  water,  under  a  polarizing  microscope,
reveals no significant ungelatinised granules, i.e., no ‘maltese crosses’ characteristic of
the starch birefringence pattern.
Solubility: practically insoluble in organic solvents. Slightly soluble to soluble in cold
water, depending on the degree of pregelatinisation. Pastes can be prepared by sifting the
pregelatinised  starch  into  stirred,  cold  water.  Cold  water  soluble  matter  for  partially
pregelatinised starch is 10-20%.
Stability  and  storage  conditions: pregelatinised  starch  is  a  stable  but  hygroscopic
material, which should be stored in a well closed container in a cool dry place.
Related substances: corn starch and pregelatinised starch; starch, sterilizable maize.
Applications: partially pregelatinised starch is a modified starch used in oral capsule and
tablet  formulations  as  a  binder,  diluents  and  disintegrants.  Both  partially  and  fully
pregelatinised starch may also be used in wet granulation processes. Fully pregelatinised
starchs can be used to make soft capsule shells and coatings as well as binders in tablets.
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                                MICROCRYSTALLINE CELLULOSE: 
Nonproprietary name: microcrystalline cellulose.
Synonyms: Avicel PH; Celex; crystalline cellulose; emcocel; tabulose.
Chemical name: cellulose.
Empirical formula: C6H10O5)n where n~220
Molecular weight: ~36000
Functional  category:  adsorbent;  suspending agent;  tablet  and capsule diluents;  tablet
disintegrant. 
Description: microcrystalline cellulose is a purified, partially depolymerized cellulose
that  occurs  as  a  white,  odorless,  tasteless,  crystalline  powder  composed  of  porous
particle. It is commercially available in different particle sizes and moisture grades that
have different properties and applications.
Solubility: slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in
water, dilute acids and most organic solvents.
Stability  and  storage  conditions:  microcrystalline  cellulose  is  a  stable  through
hygroscopic material. The bulk material should be stored in a well closed container in a
cool, dry place.
Incompatibilities:  microcrystalline  cellulose  is  incompatible  with  strong  oxidizing
agents.
Applications: it is widely used in pharmaceuticals primarily as a diluents/binder in oral
tablet  and  capsule  formulations  where  it  is  used  in  both  wet  granulations  and  direct
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compression processes. It also has some lubricant and disintegrants properties that make
it useful in tabletting. It is also used in cosmetics and food products.
Related  substances:  microcrystalline  cellulose  and  carrageenan;  microcrystalline
cellulose and carboxy methyl cellulose sodium; microcrystalline cellulose and guar gum;
powdered cellulose.
                                           SODIUM LAURYL SULFATE:
Nonproprietary name: sodium lauryl sulfate
Synonyms: dodecyl  alcohol  hydrogen  sulfate,  sodium  salt;  dodecyl  sodium  sulfate;
sodium monolauryl sulfate.
Chemical name: sulfuric acid monododecyl ester sodium salt (1:1)
Empirical formula: C12H25NaO4S
Molecular weight: 288.38
Functional category:  anionic surfactant; detergent;  emulsifying agent;  skin penetrant;
tablet and capsule lubricant; wetting agent.
Description: SLS consists of a white or cream to pale yellow colored crystals, flakes or
powder having a smooth feel, a soapy, bitter taste and a faint odor of fatty substances.
Solubility: freely soluble in water giving an opalescent solution; practically insoluble in
chloroform and ether.
Stability and storage conditions: sodium lauryl sulfate is stable under normal storage
conditions.  However,  in  solution,  under  extreme conditions,  i.e.,  pH 2.5  or  below,  it
undergoes hydrolysis to lauryl alcohol and sodium bisulfate. The bulk material should be
stored in a well closed container away from strong oxidizing agents in a cool and dry
place.
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Incompatibilities:  SLS reacts with cationic surfactants causing loss of activity even in
concentrations too low to cause precipitation. Unlike soaps, it is compatible with dilute
acids and calcium and magnesium ions. It is incompatible with salts of polyvalent metal
ions, such as aluminum, lead, tin or zinc, and precipitates with potassium salts.
Applications: SLS is an anionic surfactant employed in a wide range of nonparenteral
pharmaceutical formulations and cosmetics. It is a detergent and wetting agent effective
in both alkaline and acidic conditions. It acts as a tablet lubricant in the concentration of
1.0-2.0%
Related substances: cetosteryl alcohol; Cetyl alcohol; magnesium lauryl sulfate; wax.
                                                              POVIDONE:
Nonproprietary name: Povidone
Synonyms: kollidon; plasdone; polyvinylpyrrolidone
Chemical name: 1-Ethenyl-2-pyrrolidone homopolymer
Empirical formula: (C6H9NO)n
Molecular weight: 2500-3,000,000
Functional  category: disintegrants;  dissolution  enhancer;  suspending  agent;  tablet
binder.
Description: Povidone occurs  as  a  fine,  white  to  creamy white  colored,  odorless  or
almost odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30
are manufactured by spray-drying and occur  as  spheres.  Povidone K90 and higher  K
value Povidones are manufactured by drum drying and occurs as plates.
Solubility: freely soluble in acids,  chloroform, ethanol (95%),  ketones,  methanol and
water; practically insoluble in ether, hydrocarbons, and mineral oil.
  Arulmigu kalasalingam college of pharmacy, Page 44
Department  of pharmaceutics
                                                                                                  DRUG-EXCIPIENT PROFILE
Stability and storage conditions: Povidone darkens to some extent on heating at 150 C,
with a reduction in aqueous solubility. It is stable to a short cycle of heat exposure around
110-130 C.  Povidone  may  be  stored  under  ordinary  conditions  without  undergoing
decomposition or degradation. As the powder is hygroscopic, it should be stored in an
airtight container in a cool, dry place.
Incompatibilities: Povidone is compatible in solution with a wide range of inorganic
salts.  Natural and synthetic resins and other chemicals.  It  forms molecular adducts in
solution with sulfathiazole, sodium salicylate, salicylic acid, Phenobarbital, Tannins and
other compounds.
Applications: it is primarily used in solid dosage forms as a tablet binder, tablet diluents
or a coating agent in the concentration of 0.5-5%. Povidone is used as a suspending agent
and dispersing agent in the concentration of 5%.
Related substances: Crospovidone.
                                         COLLOIDAL SILICON DIOXIDE:
Nonproprietary name: colloidal anhydrous silica
Synonyms: aerosol, Cab-O-Sil, colloidal silica
Chemical name: silica
Empirical formula: SiO2
Molecular weight: 60.08
Functional  category:  adsorbent,  anti  caking  agent;  emulsion  stabilizer;  glidant;
suspending agent; tablet disintegrants; thermal stabilizer; viscosity-increasing agent.
Description: colloidal silicon dioxide is a submicroscopic fumed silica with a particle
size of about 15nm. It is light, loose, bluish-white colored, odorless, tasteless amorphous
powder.
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Solubility: practically insoluble in organic solvents, water, antacids, except t hydrofluoric
acid.  Soluble  in  hot  solutions  of  alkali  hydroxide.  Forms  a  colloidal  dispersion  with
water. For aerosil, solubility in water is 150 mg/L at 25 C (pH 7)
Stability and storage conditions: colloidal silicon dioxide is hygroscopic but adsorbs
large quantities of water without liquefying. Colloidal silicon dioxide powder should be
stored in a well closed container.
Incompatibilities: incompatible with diethylstilbestrol preparations.
Applications: colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and
food  products.  Its  small  particle  size  and  large  specific  area  give  it  desirable  flow
characteristics  that  are  exploited to  improve the  flow properties  of  dry powders  in  a
number of processes  such as tabletting and capsule filling.  It  acts as a glidant in the
concentration of 0.1-1%.
Related substances: hydrophobic silicon dioxide.
                                                 MAGNESIUM STEARATE:  
Nonproprietary name: magnesium stearate
Synonyms: magnesium octadecanoate; octadecanoic acid; magnesium salt.
Chemical name: octadecanoic acid magnesium salt
Empirical formula: C36H70MgO4
Molecular weight: 591.24
Functional category: tablet and capsule lubricant.
Description:  magnesium  stearate  is  a  very  fine,  light  white,  precipitated  or  milled,
impalpable  powder  of  low  bulk  density,  having  a  faint  odor  of  stearic  acid  and  a
characteristic taste. The powder is greasy to touch and readily adheres to the skin.
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Solubility:  practically  insoluble  in  ethanol,  ethanol  (95%),  ether  and  water,  slightly
soluble in warm benzene and warm ethanol (95%).
Stability  and storage conditions:  it  is  stable  and  should be  stored  in  a  well  closed
container in a cool and dry place.
Incompatibilitie: incompatible with strong acids, alkalis and iron salts. Avoid mixing
with  oxidizing  materials.  Magnesium stearate  cannot  be  used  in  products  containing
aspirin, some vitamins and most alkaloidal salts. 
Applications: magnesium stearate is widely used in cosmetics, foods and pharmaceutical
formulations.  It  is  primarily used as  a  lubricant  in capsule and tablet  manufacture at
concentrations of 0.25% and 0.5% w/w.
Related substances: calcium stearate; magnesium aluminum silicate; stearic acid; zinc
stearate.
                                                         SUCRALOSE:
Nonproprietary name: sucralose
Synonyms: sucralose; sucralosum; sucraplus
Chemical name: 1, 6-Dichloro-1, 6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-
galactopyranoside.
Empirical formula: C12H19C13O8
Molecular weight: 397.64
Functional category: sweetening agent
Description: sucralose is a white to off white colored free flowing crystalline powder.
Solubility: freely soluble in ethanol (95%), methanol and water; slightly soluble in ethyl
acetate.
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Stability and storage conditions: sucralose is a relatively stable material. In aqueous
solution at  highly acidic  conditions  (pH<3),  and  at  high temperatures  (<35 C),  it  is
hydrolyzed to a limited extent, producing 4-chloro-4-deoxygalactose and 1, 6-dichloro-1,
6-deoxyfructose. It should be stored in a well closed container in a cool, dry place at a
temperature exceeding 21 C.
Applications:  sucralose  is  used  as  a  sweetening  agent  in  beverages,  foods  and
pharmaceutical applications. It has a sweetening power of approximately 300-1000 times
that of sucrose and has no aftertaste.
Related substances: sucrose.
                                                SUNSET YELLOW:
Synonyms: FD&C yellow #6, yellow orange S
Empirical formula: C16H10N2Na2O7S2
Molecular weight: 452.37
Functional category: colorant; opacifier
Description: reddish yellow powder. Aqueous solutions are bright orange colored.
Solubility: solubility at 20 C-Acetone (1 in 38.5), ethanol (1 in 333), glycerin (1 in 5),
propylene glycol (1 in 5).
Incompatibilities:  poorly  compatible  with  citric  acid,  saccharose  solutions,  and  a
saturated bicarbonate solutions.
                                           SODIUM STARCH GLYCOLATE:
Nonproprietary name: sodium starch glycolate
Synonyms: carboxy methyl starch, sodium salt; primojel; tablo.
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Chemical name: sodium carboxymethyl starch
Functional category: tablet and capsule disintegrant.
Description: sodium starch glycolate is a white or almost free flowing very hygroscopic
powder.
Solubility: practically insoluble in methylene chloride. It gives a translucent suspension
in water.
Incompatibilities: sodium starch glycolate is incompatible with ascorbic acid.
Applications:  it  is  widely  used  in  oral  pharmaceuticals  as  a  disintegrants  in  tablet
formulations. It is commonly used in tablets prepared by either direct compression or wet
granulation process. The usual concentration employed in a formulation is between 2%
and  8%,  with  the  optimum  concentration  about  4%,  although  in  many cases  2%  is
sufficient.
                                        SODIUM STEARYL FUMARATE:
Nonproprietary name: sodium stearyl fumarate
Synonyms: fumaric  acid,  octadecyl  ester,  sodium  salt;  Pruv;  sodium  monostearyl
fumarate.
Chemical name: 2-Butenedioic acid, monooctadecyl ester, sodium salt.
Empirical formula: C22H39NaO4
Molecular weight: 390.5
Functional category: tablet and capsule lubricant.
Description: it is a fine white powder with agglomerates of flat, circular-shaped particles.
Solubility: practically insoluble in acetone, chloroform and ethanol, slightly soluble in
methanol, water (1 in 20, 000 at 25 C, 1 in 10 at 80 C, 1 in 5 at 90 Stability and
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storage conditions: at ambient temperature, sodium stearyl fumarate is stable for up to 3
years  2when store  in  amber  bottles  with  polyethylene screw caps.  The bulk material
should be stored in a well closed container in a cool and dry place.
Incompatibilities: it is reported to be incompatible with chlorhexidine acetate.
Applications: it is used as a lubricant in capsule and tablet formulations at 0.5-2.0% w/w
concentrations. It is also used in food preparations.
                                                               TALC:
Nonproprietary name: talc
Synonyms: hydrous magnesium calcium silicate; powdered talc
Chemical name: talc
Empirical formula: Mg6 (Si2O5)4(OH)4
Functional category: anti caking agent; glidant; tablet and capsule diluents; tablet and
capsule lubricant.
Description: talc is a very fine, white to grayish white, odorless, impalpable, unctuous,
crystalline powder. It adheres to the skin and is soft to touch and free from grittiness.
Solubility: practically insoluble in dilute acids and alkalis, organic solvent and water.
Stability and storage conditions: it is a stable material and can be sterilizes by heating
at 160 C for not less than 1 hour. It may also be sterilized by exposure to ethylene oxide
or gamma radiation. It should be stored in a well closed container in a cool and dry place.
Incompatibilities: incompatible with quaternary ammonium compounds.
Applications: used as a diluents and lubricant.
Widely used as a dissolution retardant in the development of controlled release product.
Topically used as dusting powder.
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Related  Substance:   Bentonite,  magnesium  aluminium  stearate,  magnesium  silicate,
magnesium trisilicate.
                                   
HYDROXYPROPYL CELLULOSE
Nonproprietary Names: Low-substituted Hydroxypropyl cellulose.
Synonyms: cellulose,  2-hydroxypropyl  ether,  2_hydroxypropyl  ether,  low-substituted
cellulose, hyperlose , low substituted L-HPC.
Chemical Name: cellulose, 2-hydroxypropyl ether(low-substituted)
Functional Category:  Tablet and capsule disintegrant, tablet binder.
Description:  Low-substituted hydroxypropyl  cellulose occurs  as  a  white  to  yellowish
white powder or granules. It is odourless or has a slight, characteristic odour and it is
tasteless.
Solubility: Practically insoluble in ethanol (95%) and in ether. Dissolves in a solution of
sodium hydroxide (1  in  10) and produces  a  viscous solution.  Insoluble but  swells  in
water.
Stability and Storage conditions: low-substituted hydroxypropyl cellulose is a stable,
though hygroscopic material. The powder should be stored in a well closed container.
Incompatibilities: Alkaline substance may interact. If a tablet formation contains such a
material, the disintegration time may be extended after storage.
Applications:
Low-substituted hydroxypropyl cellulose is widely used in oral solid-dosage forms.
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It is primarily used as a disintegrant and as a binder for tablets and granules in wet or dry
granulation.
It has been used in the preparation of rapidly disintegrating tablets produced by direct
compression methods.
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                                                          METHODOLOGY
Pre-formulation studies :
Drug-Excipient compatibility studies:
The proper design and the formulation of a dosage form require consideration of the
physical,  chemical  and  biological  characteristics  of  the  drug  and  excipients  used  in
fabricating the product. The drug and excipients must be compatible with one another to
produce a product that is stable, efficacious, attractive, easy to administer and safe.
The  compatibility  studies  provide  the  frame  work  for  the  drugs  combination  with
excipients in the fabrication of the dosage form. The study was carried out to establish
that  the therapeutically active drug has  not  undergone any changes,  after  it  has been
subjected to processing steps during formulation of tablets.
Compatibility  studies  were  carried  out  by  mixing  definite  proportions  of  drug  and
excipient and kept in glass vials, which are stored at 550C(2 weeks) and 40+20c/75±5%
RH(4 weeks).
Preparation of standard calibration curve of Deferasirox:
10mg of  drug was accurately weighed  and  transferred  to  a  100ml volumetric
flask,  volume was made up with  phosphate buffer  of  pH 6.8 containing 0.5% tween
0.2,0.4,0.6,0.8 and 1ml of the above stock solution were transferred into a series of 10ml
volumetric flasks and made up the volume with phosphate buffer of  pH 6.8 containing
0.5% tween 20 solvent system.  The absorbance values  were measured at  λmax  245nm
against phosphate buffer of pH, linearity of the standard curve was assessed from square
of  correlation  coefficient  (r2)  which  is  determined  by  least  square  linear  regression
analysis
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Pre-compression parameters60, 61
Angle of Repose:
The internal angle between the surface of the pile of blend and the horizontal surface is
known as the angle of repose.
Method:
The blend was passed through a funnel fixed to a burette stand at a height of 4cm. A
graph paper was placed below the funnel on the table. The height and radius of the pile
was measured. Angle of repose of the blend was calculated using the formula:
                                       Angle of repose (θ) = tan-1(h/r)
                       Where, h = height of the pile
                                      r = radius of the pile.
Bulk density:
The bulk density is used as a measure to describe packing materials or granules.
Method
Bulk density is the ratio of given mass of powder and its bulk volume. It was determined
by transferring an accurately an accurately weighed amount (25gm) of powder sample to
the graduated cylinder with the aid of a funnel. The initial volume was anted. Ratio of
weight of the sample to the volume it occupied was calculated.
                                     Bulk density=W/V0 g/ml
                             Where, W = mass of the blend,
                                            V0 = Untrapped volume.
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Tapped density Method:
It  was  measured  by transferring a  known quantity  (25gm) of  blend  into  a  graduated
cylinder and was placed on the tapped density apparatus. The initial volume was noted.
The apparatus was set for 500, 750 and 1250 taps. The tapped density was determined as
the ratio of mass of the blend to the tapped volume.
                                     Tapped density = W/Vf g/ml
                              Where, W = Mass of the blend 
                                             Vf = tapped volume
Compressibility index
It is the propensity of a powder to be compressed.
Method 
It  is measured by tapped density apparatus for 500, 750 and 1250 taps for which the
difference be not more than 2%. Based on the apparent bulk density and tapped density
the compressibility of the blend was determined using the following formula.
                                              % Compressibility index = [(V0-Vf)/V0] ¿ 100
                    % compressibility = [(Tapped density – Bulk density)/ Tapped density] ¿
100
Hausner ratio
It  indicates the flow properties of the powder. The ratio of tapped density to the bulk
density of the powder is called Hausner ratio.
                               Hausner ratio = Tapped density/ Bulk density
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Table 10: Flow properties and corresponding Angle of repose, Compressibility index
and Hausner ratio
S.n
o
Flow properties Angle of
repose(θ)
Compressibility Index
(%) Hausner ratio
1 Excellent 25-30 <10 1.00-1.11
2 Good 31-35 11-15 1.12-1.18
3 Fair 36-40 16-20 1.19-1.25
4 Passable 41-45 21-25 1.26-1.34
5 Poor 46-55 26-31 1.35-1.45
6 Very poor 56-65 32-37 1.46-1.59
7 Very very poor >66 >38 >1.6
Loss on drying:
The loss on drying test is designed to measure the amount of water and volatile matters in
a sample when the sample is dried under specified conditions. The loss on drying of the
blend (1g) was determined by using electronic LOD (helium lamp) apparatus at 1050C.
Evaluation parameters of Dispersible tablets
Physical appearance
The tablets were inspected for smoothness, absence of cracks, chips and other undesirable
characteristics.  If  they  are  colored,  it  includes  examination  for  mottling  and  other
evidence of uniform color distribution except where they are used intentionally.
Weight variation test
20 tablets were randomly selected from each formulation and their average weight was
calculated using digital  balance.  Individual  weight  of  each tablet  was also calculated
using the same and compared with the average weight
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Table: 11 Weight variation requirements
Average weight of tablet (mg) % Difference
130 or less 10%
From 130 to 324 7.5%
>324 5%
Hardness
The hardness  test  is  performed to  measure the tablet  strength.  Tablet  should be hard
enough to withstand packing and shipping. Schluenzier hardness tester was used for the
determination  of  hardness  of  tablets.  The  hardness  of  10  tablets  was  noted  and  the
average hardness was calculated. It is expressed in kp or kg/cm2.
Thickness:
Thickness was determined for 20 pre-weighed tablets of each batch using a digital vernier
scale and the average thickness was determined in mm. the thickness of the tablet  is
mostly related to the tablet hardness and can be used as an initial control parameter.
Percentage Friability:
The friability test gives an indication of tablets ability to resist chipping and abrasion on
handling during packaging and shipping. Usually for conventional tablets friability value
of 1.0% or less is desirable. If the weight is ≥650mg 10 tablets were taken and initial
weight was noted. The tablets were rotated in the Roche friabilator for 100 revolutions at
25rpm. The tablets were dedusted and reweighed. The tablets that loose less than 1%
were considered to be compliant. The percentage friability is expressed as the loss of
weight and is calculated by the formula:
                                                              % Friability = (A-B/B) ¿  100
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                                     Where,
                                                     A = Initial weight of tablets
                                                     B = Final weight of tablets after 100 revolutions
Uniformity of dispersion:
This test is applicable only to dispersible tablets. In this method, two tablets were placed
in 100ml of water and stirred gently until  completely dispersed.  A smooth dispersion
must be obtained which passes through a sieve screen with a nominal mesh aperture of
710µm (sieve no.22).
In vitro Disintegration studies:
Disintegration time is the time required for a tablet to breakup into granules of specified
size  (or  smaller),  under  carefully  specified  test  conditions.  The  disintegration  test  is
carried out in an apparatus containing a basket rack assembly with six glass tubes of
7.75cm length and 2.15mm in diameter the bottom of which of which consists of a 10
mesh sieve. The basket is raised and lowered 28-32 times per minute in the medium of
900ml which is maintained at37±20C.Six tablets were placed in each of the tubes and the
time required for  complete passage of  tablet  fragments  through the sieve (# 10)  was
considered  as  the  disintegration  time  of  the  tablet.  This  test  is  performed  to  ensure
disintegration of tablets in water, if it is to be used as a dispersible tablet. Dispersible
tablets  must  disintegrate  within 3  mins  when  examined by the disintegration test  for
tablets as per the compliance in the pharmacopoeia.
In vitro Dissolution studies (by UV method):
The dissolution test measures the rate of release of the drug from the dosage form  in
vitro, it is usually expressed as extent of dissolution (%drug content) occurring after a
given time under specified conditions. For effective absorption of oral solid dosage form,
simple disintegration of the dosage form is not adequate and the dissolution of the drug
into the surrounding medium plays a vital role. Though dissolution is not a predictor of
therapeutic efficacy it can be looked upon a tool which can provide valuable information
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about  biological  availability  of  drug  and  batch  to  batch  consistency.  Dissolution  is
considered  as  one  of  the  most  important  quality  control  tests  performed  for
pharmaceutical dosage form.
Instrument:
UV-Visible absorption spectrophotometer
Apparatus:
• Analytical balance
• Volumetric flasks
• Pipettes
• 0.45µm membrane filters
• Syringes
• Dissolution apparatus
• Deferasirox working standard 
• Potassium dihydrogen phosphate
• Methanol-HPLC grade
• Sodium hydroxide
• Tween-20(poly oxy ethylene sorbitan monolaurate)
• Water
Dissolution conditions:
Medium : pH 6.8 phosphate buffer containing 0.5% tween-20
Volume       : 900ml
Temperature  : 370C±0.50C
Apparatus : USP Type-II (paddle)
RPM : 50
Time intervals : 10, 20, 30 & 45min.
Procedure:
The in vitro dissolution study was carried out in the USP dissolution test apparatus, type
II (paddle). One tablet was placed in each of the six dissolution flasks containing 900ml
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of dissolution medium, previously maintained 370C ± 0.50C. After completion of each
specified  time  interval,  a  portion  of  the  solution  was  withdrawn  from zone  midway
between the surface of the dissolution medium and top of the rotating blade, not less than
1cm from vessel wall and filtered through 0.45µm membrane filter. The samples were
collected  at  specified  time  intervals  and  diluted  to  required  volume with  dissolution
medium. The absorbance of the standard and sample preparations was measured in 1cm
cells, with a suitable spectrophotometer using dissolution medium as blank preparation.
Finally the percentage drug dissolved of Deferasirox tablets was calculated.
Assay (By HPLC method)
Instrument: High performance liquid chromatography equipped with UV detector and
data handling system
Apparatus
• Analytical balance 
• Volumetric flasks
• Pipettes
• pH meter
• Filtration unit
• 0.45µm membrane filters
Chemicals and reagents
• Ammonium dihydrogen orthophosphate
• Ortho-phosphoric acid
• Purified water
• Acetonitrile-HPLC grade
• Methanol-HPLC grade
• Deferasirox working standard
Chromatographic conditions
Column :Develosil ODS HG-5(150 ¿ 4.6mm)5µm
Flow rate : 1.5ml/min
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Injection volume : 10µl
Column temperature: 400C
Runtime : 15min
Preparations:
Mobile phase preparation:
1.58g of ammonium dihydrogen ortho phosphate was accurately weighed and transferred
int  a 100ml volumetric flask.  Then 60ml of diluent was added and was dissolved by
sonication. The solution was cooled to the room temperature and diluted to the volume
with diluent. 2ml of the above solution was transferred into a 100ml volumetric flask and
diluted to the required volume with diluent.
Diluent preparation:
Acetonitrile and methanol were mixed in the ratio of 50:50v/v respectively.
Standard preparation:
40mg of deferasirox working standard was accurately weighed and transferred into a
100ml  volumetric  flask.  Then  60ml  of  diluent  was  added  and  was  dissolved  by
sonication. The solution was cooled to the room temperature and diluted to the required
volume with diluent .2ml of the above solution was transferred into a 100ml volumetric
flask and diluted to the required volume with diluent.
Sample preparation;
20 tablets were accurately weighed and finally powdered.  From this  powdered tablet
equivalent to 400mg of deferasirox was weighed and transferred into a 250ml volumetric
flask, to this 180ml of the diluent was added and sonicated for 30 mins with occasional
stirring. Then the solution was cooled to room temperature and diluted to the required
volume with diluent. The solution was filtered through 0.45µm membrane filter. 1ml of
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the above filtered solution was transferred into a 200ml volumetric flask and diluted to
the required volume with diluent.
Procedure:
Equal  volumes  (10µl)  of  the  diluent  as  blank,  standard  preparation  and  sample
preparations were injected separately into the chromatograph, the chromatograms were
recorded and the peak area responses for the major peaks were measured. Finally the
percentage content of deferasirox in the portion of the deferasirox tablets was calculated.
       % Content of deferasirox = TA X SW X 2 X 250 X 200 X P X Avg.wt X 100 
                          SA X 100 X 100 X TW X 1 X 100 X LA
Where,
TA = Peak area response due to deferasirox from sample preparation.
SA = Peak area response due to deferasirox from standard preparation.
SW = Weight of deferasirox working standard taken in mg.
TW = Weight of sample taken in mg.
P = Purity of deferasirox working standard.
Avg. wt.= Average weight of deferasirox tablet taken in mg.
LA = Label amount of deferasirox.
Water content (By KF method)
Instrument: Karl Fischer titrator
35ml of a mixture of methanol was transferred to the titration vessel and titrated with
Karl Fischer reagent to the electrometric end point, to consume any moisture that may be
present  (  disregard  the  volume  consumed,  since  it  does  not  enter  into  calculation).
Powder  from  5  tablets  was  used,  ground  to  a  fine  powder  in  an  atmosphere  of
temperature and relative humidity known not to influence the results. 300-500mg of the
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powder  was  accurately  weighed  and  transferred  into  the  titration  vessel,  mixed  and
titrated with Karl Fischer reagent to the electrometric end point. Finally the water content
of the specimen in mg was calculated.
Stability studies:
The purpose of stability testing is to provide evidence of the quality of the drug substance
or  drug  product  and  how  it  varies  with  time  under  the  influence  of  a  variety  of
environmental conditions (heat, humidity, light, air etc.). The formulation was packed in
suitable  packing like  blister  and  strips  packs  and  then  they will  be  kept  at  different
temperature, humidity conditions and the samples will be analyzed for their physical and
chemical properties.
The formulation is subjected to 
• Long-term testing at 25±20C and 60±5% RH for 12 months
• Accelerated testing at 40±20C and 75±5% RH for 6 months
Innovator product details:
Innovator  product  details  including  their  manufacturer  name,  description,  physical
parameters and dissolution profile were given in the following table
Table 12: Innovator product details
Name of the product ASUNRA 400mg
Manufacturer name Novartis Pharma Stein AG, Switzerland
Color Off white
Description Off white square shaped tablet, debossed with NRS on
one side and J400 on other side
Package Alu-Alu blister pack. Each carton contains 5 blister packs
and each blister contains 6 tablets (5×6=30 tablets)
Table: 13 Physical parameters of innovator product
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Parameters 400mg
Weight of the tablet (mg) 1392
Thickness( mm) 5.31
Hardness (kp) 7.2
Length (mm) 17.9
Diagnol (mm) 20.95
Disintegration time (sec) 33
Dispersion time (sec) 60
Table no: 14 Dissolution Profile of Innovator Product (ASUNRA)
Time (min)
Cumulative Percentage Drug
Release
10 79.7
20 86.4
30 92.1
45 98.6
Characterization of Active pharmaceutical ingredient (API)
Table 15: Active pharmaceutical ingredients characterization
Tests Results
Description Off white crystalline powder
Solubility
Freely soluble in dimethyl formamide and dimethyl
sulfoxide, slightly soluble in methanol, practically insoluble
in water.
Angle of repose 39.41
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Bulk density (gm/ml) 0.460
Tap density (gm/ml) 0.795
Compressibility index
(%) 42.105
Hausner ratio 1.727
Loss on drying 0.10% w/w
FORMULATION  DEVELOPMENT  OF  DEFERASIROX  DISPERSIBLE
TABLETS
Direct compression method:
Table 16: Formula for F-1
S.No
.
Ingredient mg/tab(F-1)
1 Deferasirox 400
2 Lactose monohydrate 144
3 Crospovidone 50
4 MCC pH102 300
5 Starch 1500 30
6 SLS 6
7 Aerosil 10
8 Magnesium stearate 10
Procedure for Formulation 1:
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• All the ingredients were weighed except  Aerosil  and Magnesium stearate and
were passed through #40 mesh, then mixed for 2 mins in a blender.
• The above mixture was pre lubricated using Aerosil for 5mins and then lubricated
with magnesium stearate in blender for 2mins.
• Then the lubricated was compressed using 15mm round flat punches.
Wet granulation method 1
Table 17: Formula for F-2, F-3, F-4, F-6, F-7,F-8.F-9
S.No
.
Ingredient F-2 F-3 F-4 F-6 F-7 F-8 F-9
1. Deferasirox 400 400 400 400 400 400 400
2. Lactose
monohydrate 97 97 97 97 - - -
3. Crospovidon
e XL 25 30 35 50 100 100 100
4. MCC pH 101 333.5 308.5 303.5 258.5 305.5 292 292
5. Starch 1500 - - - 30 30 30 30
6. PovidoneK30 25 45 45 45 45 45 45
7. SLS 6 6 6 6 6 6 6
8. Sucralose - - - - - 8 8
9. Water q.s q.s q.s q.s q.s q.s q.s
10. Color - - - - - 0.5 0.5
11. Aerosil 9 9 9 9 9 9 9
12. Flavour - - - - - 5 5
13. Magnesium
stearate 4.5 4.5 4.5 4.5 4.5 4.5 4.5
 
Procedure for Formulation 2:
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• API, Lactose monohydrate, SLS, Crospovidone XL, MCC pH 101 were weighed
and mixed for 2mins.
• The above mixture was passed through #40mesh.
• Povidone K30 was dispersed in sufficient quantity of purified water by stirring.
• Then the above mixture was granulated using binder solution (Povidone K30 and
water)
• The wet mass was passed through #12 mesh.
• The sieved mixture was dried using Fluid Bed Drier  and the temperature was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%
• The  dried  blend  was  passed  through  #18mesh  and  then  pre  lubricated  using
Aerosil  for  5min  and  then  lubricated  with  magnesium stearate  in  blender  for
2mins.
• Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
Procedure for Formulation 3:
• API, lactose monohydrate, SLS, Crospovidone XL, MCC pH101 were weighed
and mixed for 2mins.
• The above mixture was passed through #40mesh.
• Povidone K30 was dispersed in sufficient quantity of purified water by stirring.
• Then the above mixture was granulated using binder solution( Povidone K30 and
water).
• The wet mass was passed through #12 mesh.
• The sieved mixture was dried using Fluid Bed Drier  and the temperature was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%
• The  dried  blend  was  passed  through  #18mesh  and  then  pre  lubricated  using
Aerosil  for  5min  and  then  lubricated  with  magnesium stearate  in  blender  for
2mins.
• Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
Procedure for Formulation 4:
•API, lactose monohydrate, SLS, Crospovidone XL, MCC pH101 were weighed and
mixed for 2mins.
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       • The above mixture was passed through #40mesh.
       • Povidone K30 was dispersed in sufficient quantity of purified water by stirring.
       • Then the above mixture was granulated using binder solution ( Povidone K30 and
water).
       • The wet mass was passed through #12 mesh.
       • The sieved mixture was dried using Fluid Bed Drier  and the temperature was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%.
• The  dried  blend  was  passed  through  #18mesh  and  then  pre  lubricated  using
Aerosil  for  5min  and  then  lubricated  with  magnesium stearate  in  blender  for
2mins.
       • Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
Wet granulation method 2
Table 18: Formula for F-5
S.No.                                 Ingredient             mg/tabs(F-5)
1. Deferasirox 400
2. SSG 80
3. MCC pH 101 302
4. L-HPC-LH11 44
5. Tween 80 4
6. Povidone K30 45
7. Water q.s
8. Aerosil 10
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9. SSF 6
10. Talc 9
                                      Total 900
Procedure for Formulation 5:
• API, SSG, MCC pH101, Hydroxy propyl cellulose (L-HPC-LH11) were weighed
and mixed for       2mins.
        • The above mixture was passed through #40mesh.
•  The binder was prepared by dispersing povidone K30 and tween 80 in sufficient
quantity of water.
• The binder solution was added to the dry mixture until a wet mass is formed.
        • Then the above mixture was granulated using binder solution ( Povidone K30 and
water).
        • The wet mass was passed through #12 mesh.
        • The sieved mixture was dried using Fluid Bed Drier  and the temperature was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%
• The dried mass mixture was passed through #18mesh.
• The sieved mixture was lubricated with SSG, Aerosil and Talc first for 2mins and
then mixed with SSF for 1-2mins.
• Then the lubricated blend was passed through #40mesh.
        • Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
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Procedure for Formulation 6:
• API,  lactose monohydrate,  Starch 1500, Crospovidone XL,  MCC pH101 were
weighed and mixed for 2mins.
• The above mixture was passed through #40mesh.
• Povidone K30 was dispersed in sufficient quantity of purified water by stirring.
• Then SLS was added to the binder solution and was allowed to dissolve.
• The binder solution was added to the dry mixture.
• The wet mass was passed through #12mesh.
• The sieved mixture was dried using Fluid Bed Drier  and the temperature was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%.
• The dried mass mixture was passed through #18mesh.
• The sieved mixture was lubricated with Aerosil, crospovidone XL and SLS for
2min.
• Magnesium  stearate  was  passed  through  #40  mesh  and  added  to  the  above
mixture and then mixed for 2mins.
• Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
Procedure for Formulation 7:
• API, Starch 1500, Crospovidone XL, MCC pH101 were weighed and mixed for
2mins.
• The above mixture was passed through #40mesh.
• The binder was prepared by dispersing povidone K30 in sufficient quantity of
water.
• Then SLS was added to the binder solution and was dissolved by stirring.
• The binder solution was added to the dry mixture.
• The wet mass was passed through #12mesh.
• The sieved mixture was dried using Fluid Bed Drier  and the temperature was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%.
• The dried mass mixture was passed through #18mesh.
• The sieved mixture was lubricated with Aerosil, crospovidone XL and SLS for
2min.
• Magnesium  stearate  was  passed  through  #40  mesh  and  added  to  the  above
mixture and then mixed for 2mins.
• Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
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Procedure for Formulation 8:
• API, Sucralase, Starch 1500, Crospovidone XL, MCC pH101 were weighed and
mixed for 5mins.
• The above mixture was passed through #40mesh.
• The binder was prepared by dispersing povidone K30, SLS and Colour slowly in
sufficient quantity of water by stirring.
• The binder solution was added to the dry mixture.
• The wet mass was passed through #12mesh.
• The sieved mixture was dried using Fluid Bed Drier  and the temperature was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%.
• The dried mass mixture was passed through #18mesh.
• The  sieved  mixture  was  lubricated  with  Aerosil,  Crospovidone  XL,  SLS  and
Flavour for about 3 minutes and was passed through #40 mesh.
• Magnesium  stearate  was  passed  through  #40  mesh  and  added  to  the  above
mixture and then mixed for 2mins.
• Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
Procedure for Formulation 9:
• API, Sucralase, Starch 1500, Crospovidone XL, MCC pH101 were weighed and
mixed in RMG for 5mins.
• The impeller was adjusted to slow.
• The binder was prepared by dispersing povidone K30, SLS and Colour slowly in
sufficient quantity of water by stirring.
• The binder solution was added to the dry mixture within 2mins with impeller fast.
• The wet mass was mixed for 1min with impeller and chopper fast.
• The  wet  mass  was  dried  using  Fluid  Bed  Drier  and  the  temperature  was
maintained at 600C until the moisture content in the blend comes to 1.0 to 2.0%.
• The dried mass mixture was passed through #18mesh.
• The sieved mixture was lubricated with SLS, Aerosil, Crospovidone XL, Flavour
and Magnesium stearate in a blender.
• Then  finally  the  lubricated  blend  was  compressed  using  15mm  round  flat
punches.
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                                      RESULTS AND DISCUSSION
The present investigation was undertaken to formulate deferasirox into dispersible tablet
for  the  treatment  of  chronic  iron  overload.  For  the  development  and  formulation  of
dispersible tablets, wet granulation and direct compression techniques were carried out
with  combination  of  various  approved  excipients.  All  the  experimental  formulation
batches  have  been  subjected  to  various  evaluation  parameters  viz,  average  weight,
thickness,  hardness,  friability,  disintegration,  uniformity  of  dispersion,  dissolution
studies, water content and assay.
Formulation F-1 was carried out by direct compression method using ingredients such
as lactose mono hydrate, Crospovidone XL, MCC pH 102, Starch 1500, SLS, Aerosil and
Magnesium  stearate.  Here  poor  flow  property  was  observed,  hardness  and  friability
values were also not satisfactory. The disintegration time and dispersion time were found
to be 36 and 71 sec respectively. The percentage of drug release was 88.8% (in 45 mins)
and it does not comply with the innovator product. So, we planned to forward the next
batch using wet granulation method.
Formulation F-2 was carried out by wet granulation technique. Here Povidone K30 was
used as a binder which was dispersed in water to make a solution. The other excipients
are same as the previous formula except MCC pH 102 which is replaced by MCC pH101
and  starch  (excluding  from  the  formulation).  In  this  formula  both  the  binder  and
superdisintegrant concentrations were taken as 25mg/tab each. Here hardness was found
to  be  less  and  the  friability  value  does  not  comply  with  the  specifications.  The
disintegration time and dispersion time were found to be 40 and 63sec respectively. The
percentage of drug release was 87.9% (in 45mins) and it was found to be less when to
compared  with  the  innovator  product.  So,  we  planned  to  forward  the  next  batch  by
increasing both the binder and superdisintegrant concentrations.
Formulation F-3 was carried out by using the same excipients as that of the previous
formula. Here binder and super disintegrant concentrations were raised to 45mg/tab and
30mg/tab respectively.  Improvement in the hardness was observed. The disintegration
time (62 sec) and dispersion time (118 sec) does not comply with the innovator product.
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The percentage of  drug release was found to  be 86.4 %( in 45 mins).  So,  for  better
disintegration  the  next  batch  was  planned  by  increasing  super  disintegration
concentration.
Formulation F-4 was carried out by using the same excipients as that of the previous
batch.  Here  the  binder  was  same  as  the  previous  batch  but  the  superdisintegrant
concentration was raised to 35mg/tab. Then also the disintegration and dispersion of the
compressed tablets was slightly poor i.e. a small amount of substance was retained on the
sieve while passing through sieve no.22. It indicates that this batch also fails the specific
test for dispersible tablets. The disintegration time and dispersion time were found to be
58 and 109sec respectively. The percentage of drug release was 89.3 %(in 45mins) and it
does  not  comply with  the  innovator  product.  So,  the  next  batch  was  carried  out  by
changing the formula.
Formulation F-5 was made by using a new formula i.e. hydroxyl propyl cellulose (L-
HPC_LH11), SSG, Magnesium stearate, Talc and SSF. The binder solution was prepared
by dispersing Povidone K30 and Tween *0. The disintegration time and dispersion time
were 67 sec and 125 sec respectively. Even though SSG was used as a superdisintegrant,
poor dispersion was occurred and the residue was retained on the sieve when it  was
passed through sieve no.22. The percentage of drug release was found to 73.6 %( in 45
mins) and it does not comply with the innovator product. So, in order to get a better
dispersion the next batch was planned by incorporating starch 1500 and increasing the
concentration of superdisintegrant.
Formulation F-6 was made by using the same formula as that of F-4 and additionally
starch 1500 was added. Here the superdisintegrant concentration was raised to 50mg/tab.
The disintegration time and dispersion time were found to be 49 and 92 sec respectively.
Even though starch 1500 was added to the formula for better dispersion still amount of
residue remained on the sieve while passing. The percentage of drug release was 91.4%
(in 45 mins) and it  does not comply with  the innovator  product.  So, next batch was
planned  by  excluded  lactose  monohydrate  and  increasing  the  concentration  of
superdisintegrant.
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Formulation  F-7 was  made  by  using  the  same  formula  of  the  previous  batch  by
excluding lactose monohydrate and the concentration of superdisintegrant was increased
to 100mg/tab.  The disintegration  time (32sec)  and  the  dispersion  time (65  sec)  were
found to be satisfactory and the percentage of drug release (97.2%) also improved by
comparing  with  the  previous  batches  and  it  was  found  to  match  with  the  innovator
product. Here the dispersed mixture passed freely from sieve without any residue. So, the
next batch was performed by adding colour,  flavor and sweetener for better taste and
appearance of the tablet.
Formulation F-8 was performed by using the same formula of the previous batch by
including colour, flavor and sweetener. This batch was taken to improve the appearance
as well as for better acceptability. The disintegration time (35sec), dispersion time (67
sec) and the percentage of drug release(98.3% in 45mins) were found to be satisfactory
and  it  matches  with  innovator  product(  ASUNRA).  So,  the next  batch  performed by
increasing the batch size to check the reproducibility.
Formulation F-9 was performed by using the same formula of the previous batch by
increasing the batch size for reproducibility. The disintegration time (34sec), dispersion
time (62sec) and percentage of drug release (97.4% in 45 mins) matches with that of the
innovator (ASUNRA). Then the formulated tablets were loaded for stability as per ICH
guidelines.
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              Figure7:FTIR specta of deferasirox
           Figure8:  FTIR sprctra of deferasirox and polymers
  HPLC method: 
                      
Figure9:Sample name deferasirox assay in Blank
Table no19.:Deferasirox assay blank:
S.no Peak Name Vial RT RT Area %Area Height(µV
Arulmigu kalasalingam college of pharmacy Page 75
Department  of pharmaceutics
                                                                                                                         RESULTS &DISSCUSSION  
Ratio )
1 Deferasiro
x
Deferasirox assay standard:
                  
Figur10.:Standard graph 
Table no20.Assay standard:
Peak
name
Via
l RT
RT
Rati
o
Area %are
a
Heigh
t
(µv)
USP
Tailin
g
USP
Plate
count
USP
Resol
ution
Deferasiro
x
3
6.15
2
49634
9
100.0
0
43872 1.14 6879
Assay of deferasirox sample:
                    
 Figure11:Sample of deferasirox 
Arulmigu kalasalingam college of pharmacy Page 76
Department  of pharmaceutics
                                                                                                                         RESULTS &DISSCUSSION  
Table no21:Assay of deferasirox in sample:
Peak name Vial RT
RT
Rati
o
Area %area
Height(µv
)
USP
Tailing
USP
Plate
coun
t
USP
Resol
ution
Deferasiro
x
4
6.15
3
49868
6
100.00 39784 1.13 6899
                                   Pre-formulation studies
Table 22: Drug-excipient compatibility studies
S.N
o
Ingredients Ratio
Description
Initial 550C(2 weeks) 40±2
0CC/75±5
%
1. API 1 Off white No change No change
2. Lactose monohydrate 1 Off white No change No change
3. Crospovidone XL 1 White No change No change
4. Starch 1500 1 White No change No change
5. MCC pH 101 1 Off White No change No change
6. SLS 1 White No change No change
7. Povidone K30 1 Off white No change No change
8. Aerosil 1 White No change No change
9. Magnesium stearate 1 White No change No change
10. L-HPC-LH11 1 White No change No change
11. SSG 1 White No change No change
12. Tween 80 1 Pale yellow No change No change
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13. SSF 1 White No change No change
14. Talc 1 White No change No change
15. Sucralose 1 White No change No change
16. Orange flavor 1 Off white No change No change
17. Sunset yellow (SUPRA) 1 Reddishyellow No change No change
18. API+Crospovidone XL 5:1 Off white No change No change
19. API+Starch 1500 5:1 Off white No change No change
20. API+MCC pH101 1:5 Off white No change No change
21. API+SLS 5:1 Off white No change No change
22. API+Povidone K30 5:1 Off white No change No change
23. API+Aerosil 5:1 Off white No change No change
24. API+Magnesium
stearate 5:1 Off white No change No change
25. API+L-HPC-LH11 5:1 Off white No change No change
26. API+SSG 5:1 Off white No change No change
27. API+Tween 80 5:1 Pale yellow No change No change
28. API+SSF 5:1 Off white No change No change
29. API+Talc 5:1 Off white No change No change
30. API+Sucralose 5:1 Off white No change No change
31. API+Orange flavor 5:1 Off white No change No change
32. API+Sunsetyellow(SUPRA) 5:1 Pale pink No change No change
Table 23: Post compression parameters for formulations F-1 to F-9
Formula Avg.weight Thickness Hardness (kp) Friability (%)
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(mg) (mm)
F-1 952.6 4.97 4.02 1.92
F-2 904.1 4.52 4.13 1.99
F-3 897.2 4.31 5.48 0.62
F-4 901.0 4.27 5.52 0.39
F-5 905.7 4.60 5.44 0.50
F-6 903.0 4.38 5.79 0.31
F-7 902.0 4.36 5.85 0.29
F-8 903.4 4.43 5.80 0.23
F-9 903.0 4.41 5.89 0.20
F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9
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              Figure 12: Comparison of average weight of different formulations.
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Figure 13: Comparison of thickness of different formulations
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       Figure 14: Comparison of Hardness of different formulations
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Figure 15: Comparison of percentage Friability of different formulations
Table 24: Disintegration time, Dispersion time, Water content and Assay values for
 Formulations F-1 to F-9.
Formula Disintegration
time(sec)                  
Dispersion  time
(sec)
 Water  content
(w/w)
Assay
(%)
F-1 36 71 3.5 99.8
F-2 40 63 3.1 98.3
F-3 62 118 4.2 101.0
F-4 58 109 3.6 99.5
F-5 67 125 4.3 100.7
F-6 49 92 4.0 98.1
F-7 32 65 3.7 99.7
F-8 35 67 3.4 100.2
F-9 34 62 3.5 99.98
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Figure 16: Comparsion of Disintegration time of different formulations
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Figure17:Comparision of Dispersion time of different formulation
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Table no;25 Dissolution profiles of different formulations (F-1 to F-9)
Sampling
time(min
)
Cumulative Percentage Drug Release
F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9
10 72.5 50.7 49.6 54.9 56.8 69.6 78.4 77.2 78.0
20 78.0 66.4 63.3 70.0 60.2 80.5 84.3 84.8 85.1
30 83.6 78.5 74.1 79.5 65.3 87.7 90.1 91.4 90.6
40 88.8 87.9 86.4 89.3 73.6 91.4 97.2 98.3 97.4
               
                                                  Time(min)
Figure 18: Dissolution Profile of Deferasirox Innovator (ASUNRA)
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            Figure19: Dissolution Profile of formulation 1-4 compared with innovator
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Figure 20: Dissolution profile of formulation 5-9 compared with innovator
Selection of Final formula:
• Based on, ƒ2  values (similarity factor) comparative with reference product final
formula was selected.
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  Table 26: Similarity (ƒ1) and difference (ƒ2) factors for various formulations are 
F1 F2 F3 F4 F5 F6 F7 F8 F9
Differenc
e  factor
(ƒ1)
9.5 20.5 23.37 17.68 28.27 7.73 1.90 1.42 1.59
Similarity
factor (ƒ2)
53.31 35.33 32.98 38.69 29.85 56.8 84.9 86.8 50
STABILITY DATA:
Table 27: Physical and chemical parameters of Deferasirox dispersible tablets (F-9)
after 1st and 2nd month 40±20C/75±5%RH (Packing: HDPE Bottle)
Parameter Initial 1 month 2 month
Description Light  orange
coloured  round
shaped  uncoated
tablets 
No change No change
Avg.wt (mg) 903.0 903.2 903.4
Hardness (kp) 5.89 5.83 5.77
Thickness (mm) 4.41 4.48 4.53
Friabilty (%) 0.20 0.23 0.26
Water content (w/w) 3.7 3.8 3.5
Assay(%) 99.98 100.5 99.47
Table 28: Dissolution  profiles of Deferasirox dispersible tablets (F-9) after 1st and
2nd month at 40±20C/75±5%RH(Packing: Blister pack)
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Time
interval(min)
                      Cumulative percentage drug release
Initial 1 month 2 month
10 78.0 78.12 78.4
20 85.1 84.3 84.7
30 90.6 91.4 91.9
40 97.4 97.1 96.6
Table 29: Physical and chemical parameters of Deferasirox dispersible tablets (F-9)
after 1st and 2nd month 40±20C/75±5%RH (Packing: Blister pack)
Parameters Initial 1 month 2 month
Description Light  orange  coloured
round  shaped  uncoated
tablets
No change No change
Avg.wt (mg) 903.0 903.2 903.1
Hardness (kp) 5.89 5.86 5.82
Thickness (mm) 4.41 4.50 4.54
Friability (%) 0.20 0.24 0.23
Water  content
(w/w)
3.7 3.6 3.8
Assay (%) 99.98 100.2 99.41
Table 30: Dissolution profiles of Deferasirox dispersible tablets (F-9) after 1st and 2nd
month at 40±20C/75±5% RH (Packing: Blister pack)
 
 Time  interval
(min)
                             Cumulative percentage drug release
            Initial           1month         2month
10 78.0 78.4 78.7
20 85.1 85.6 84.9
30 90.6 90.0 89.5
40 97.4 96.9 96.3
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Figure21:Graphical  representation  of  Dissolution  profiles  of  stability  studies
conducted at 40±50C /75±5% RH for formulation 9(Packing: HPDE Bottle)
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 Figure no.22:Graphical  representation of  Dissolution profiles of  stability  studies
conducted at 40±50C /75±5% RH for formulation 9(Packing: Blister pack)
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                                   SUMMARY AND CONCLUSION
The  topic  for  the  present  study  is  “Formulation  Development  and  Evaluation  of
Deferasirox dispersible tablets”.
Introduction is presented in  chapter 1 which gives details about chronic iron overload
and its  mode and  choice of  drugs for  the treatment  of chronic iron overload.  This
chapter  also  gives  the  overall  view  about  dispersible  tablets  and  their  methods  of
development.
Aim and Objective is presented  which gives the information regarding the present study.
Literature of review is presented in  which provides an extensive detail of the related
research work pertaining to the present study.
Drug  profile is  presented   which  gives  details  about  the  mechanism  of  action,
pharmacodynamics, dosage and administration, precautions and side effects of the drug
selected.
Excipient  profile  which  gives  details  about  the  different  excipients  used  in  the
formulation development.
Materials and methods  which gives details about the list of chemicals, equipments used
for  the study.  This  chapter  also gives  information about the methods involved in the
development of formulation.
Experimental investigation  which gives information about different formulas developed
in the formulation of dispersible tablets and the comparative evaluation of the developed
formulation with that of the innovator product.
Results and discussion  which deals with the completed information regarding physical
and chemical analysis of the present study with suitable tables, graphs and figures.   
Summary and conclusion  which provides detailed information about each chapter.
Deferasirox  is  indicated  in  for  the  treatment  of  chronic  Iron  overload  due  to  blood
transfusions in adult and pediatric patients (aged 2 years and over).
Pre-formulation studies were performed for the drug and excipients as per the standard
procedures.
The innovator product characterization was performed.
Formulation 1 was made by direct compression method. In this poor flow property was
observed and also hardness and friability values were not satisfactory.
Formulations 2,3,4,6,7,8,9 were made by using wet granulation method. In formulaton2
hardness  was  found  to  be  less  and  the  friability  value  does  not  comply  with  the
specifications. In formulations 3, 4, 6 in order to get a better dispersion the concentration
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of  superdisintegrant  was  increased.  Here  the  disintegration  time,  dispersion  time  and
percentage of drug release does not comply with the innovator product. In formulations
7,8,9 the disintegration time, dispersion time and percentage of drug release were found
to  match  with  the  innovator  product.  All  the  physicochemical  characteristics  of  the
finished product were found to be satisfactory.
Formulation 5 was also made by wet granulation method with a different formula. Here
the disintegration time, dispersion time and percentage drug release does not match with
the innovator.
All  the  formulations  were  subjected  to  physicochemical  analysis  and  out  of  them
Formulation 8 was found to be satisfactory when compared to other formulations. The
disintegration time (35  sec),  dispersion  time (67  sec)  and  percentage of  drug release
(98.3%) were found to be satisfactory and it matches with the innovator. So, the batch
size was increased in further trial to check the reproducibility (Formulation 9). Finally
loaded for stability as per the ICH guidelines.
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